

Customer Number: 000959

DIVISIONAL-CONTINUATION APPLICATION TRANSMITTAL FORM
UNDER RULE 1.53(b) (former Rule 1.60)

DOCKET NUMBER	ANTICIPATED CLASSIFICATION OF THIS APPLICATION:		PRIOR APPLICATION SERIAL NUMBER: 08/755,584	PRIOR APPLICATION FILING DATE: NOVEMBER 25, 1996
HUI-026DV	CLASS:	SUBCLASS:	EXAMINER: B. CAMPELL	ART UNIT: 1632

ASSISTANT COMMISSIONER FOR PATENTS
 BOX PATENT APPLICATION
 WASHINGTON, DC 20231

CERTIFICATION UNDER 37 CFR 1.10

Date of Deposit: November 16, 1998 Mailing Label Number: EL094330958US

I hereby certify that this 37 CFR 1.53(b) request and the documents referred to as attached therein are being deposited with the United States Postal Service on the date indicated above in an envelope as "Express Mail Post Office to Addressee" service under 37 CFR 1.10 and addressed to the Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

Viriato G. Cardoso
 Name of Person Mailing Paper

Viriato G. Cardoso
 Signature of Person Mailing Paper

Dear Sir:

This is a request for filing a ☐ continuation ☒ divisional application under 37 CFR 1.53(b), of pending prior application serial no. 08/755,584 filed on November 25, 1996, of Laurie H. Glimcher and Martin R. Hodge entitled NAFT-Interacting Proteins NIP45 and Methods of Use Therefor

- ☒ Enclosed is a copy of the latest inventor signed application, including the oath or declaration as originally filed in parent application Serial No.: 08/755,584. The copy of the enclosed papers is as follows:
 - ☒ 43 page(s) of specification
 - ☒ 5 page(s) of claims
 - ☒ 1 page(s) of abstract
 - ☒ 14 sheet(s) of drawing
 - ☒ 12 page(s) of declaration and power of attorney.
- ☒ Two verified statements to establish small entity status under 37 CFR 1.9 and 1.27, copies of which is enclosed, was filed in the prior application USSN 08/755,584 and such status is still proper and desired (37 CFR 1.28(a)).
- ☒ The filing fee is calculated below:

	NUMBER OF CLAIMS FILED		NUMBER EXTRA
TOTAL	* 25	MINUS **	20 = 5
INDEP.	* 8	MINUS ***	3 = 5
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS			

SMALL ENTITY

RATE	FEE
x 9 =	\$ 45.00
x 39 =	\$ 195.00
+135 =	\$ 5.00
BASIC FEE	\$380.00
TOTAL	\$620.00

OTHER THAN A SMALL ENTITY

RATE	FEE
x 22 =	\$ 0.00
x 82 =	\$ 0.00
+ 270 =	\$ 0.00
BASIC FEE	\$ 0.00
TOTAL	\$ 0.00

OR


4. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 12-0080. A duplicate copy of this sheet is enclosed.
5. ☒ A check in the amount of \$620.00 is enclosed for payment of the filing fee.
6. ☒ Cancel in this application original claims 1-25, 37, 38, 44 and 45 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
7. ☒ A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claims in the prior application.)
8. ☒ Amend the specification by inserting before the first line the sentences: "This application is a divisional application of serial no. 08/755,584 filed on November 25, 1996, pending. The contents of the aforementioned application is hereby incorporated by reference."
9. ☐ Please abandon said prior application as of the filing date accorded this application. A duplicate copy of this transmittal is enclosed for filing in the prior application file. (May be used if signed by person authorized by §1.138 and before payment of base issue fee.)
10. ☒ The prior application is assigned of record to President and Fellows of Harvard College and was recorded at reel 8556, frame 0549 in USSN 08/755,584.
11. ☐ A _____ month extension of time has been submitted in the parent application Serial No. _____ in order to establish copendency with the present application.
12. ☒ The power of attorney in the prior application is to Giulio A. DeConti, Jr., Catherine J. Kara and Lahive & Cockfield, LLP.
- a. ☒ The power appears in the original papers in the prior application.
- b. ☐ Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- c. ☒ An associate power has been executed and is attached.
13. ☒ Address all future communications (May only be completed by applicant, or attorney or agent of record) to Giulio A. DeConti, Jr. & Catherine J. Kara at Customer Number: **000959** whose address is:

Lahive & Cockfield, LLP
28 State Street
Boston, Massachusetts 02109

14. ☒ Any requests for extensions of time necessary in a parent application for establishing copendency between this application and a parent application are hereby requested and the Commissioner is authorized to charge any fee associated with such an extension to Deposit Account No. 12-0080.
15. ☒ Pursuant to 37 CFR 1.821(e), the computer readable form of the sequence listing for this new application is to be identical with the computer readable form of application serial no. 08/755,584. Please use the computer readable form of application serial no. 08/755,584 in lieu of filing a duplicate computer readable form in this application. Pursuant to 37 CFR 1.821(f), the content of the paper copy of the sequence listing for this new application and the computer readable form of application serial no. 08/755,584 are the same.

November 16, 1998
Date

LAHIVE & COCKFIELD, LLP
28 State Street
Boston, Massachusetts 02109
Tel. (617) 277-7400
REPRODUCED FROM OFFICE COPY


Megan E. Williams
Reg. No. 43,270
☐ inventor(s) ☐ filed under §1.34(a)
☐ assignee of complete interest
☒ attorney or agent of record

09192611-111698

Applicant or Patentee: Laurie H. Glimcher and Martin R. Hodge Attorney's
Serial or Patent No.: 08/755,584 Excerpt No.: HUI-026
Filed or Issued: November 25, 1996
Title: NFAT-INTERACTING PROTEIN NIP45 AND METHODS OF USE THEREFOR

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) and 1.27(c)) - SMALL BUSINESS CONCERN

I hereby declare that I am

- ☐ the owner of the small business concern identified below:
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF SMALL BUSINESS CONCERN Boston Life Sciences
ADDRESS OF SMALL BUSINESS CONCERN 31 Newbury Street, Suite 300
Boston, Massachusetts 02116

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention described in:

- ☐ the specification filed herewith with title as listed above.
☒ the application identified above.
☐ the patent identified above.

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights in the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

NAME President and Fellows of Harvard College
ADDRESS 124 Mt. Auburn Street, Cambridge, MA 02138
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☒ NONPROFIT ORGANIZATION

NAME _____
ADDRESS _____
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Marc Lamer MD
TITLE OF PERSON OTHER THAN OWNER Executive Vice President
ADDRESS OF PERSON SIGNING Boston Life Sciences, Inc.; 31 Newbury St., Boston MA 02116
SIGNATURE [Signature] DATE 9/30/97

Applicant or Patentee: Laurie H. Glimcher and Martin R. Hodge

Page No. _____

Serial or Patent No.: 08/755,584

Document No.: HUI-026

Filed or Issued: November 25, 1996

Title: NFAT-INTERACTING PROTEIN NIP45 AND METHODS OF USE THEREFOR

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) and 1.27(d)) - NONPROFIT ORGANIZATION**

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF NONPROFIT ORGANIZATION President and Fellows of Harvard College

ADDRESS OF NONPROFIT ORGANIZATION 124 Mt. Auburn Street, Cambridge, MA 02138

TYPE OF NONPROFIT ORGANIZATION

- ☒ UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION
☐ TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501(a) and 501(c)(3))
☐ NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA
(NAME OF STATE _____)
(CITATION OF STATUTE _____)
☐ WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501(a) and 501(c)(3)) IF LOCATED IN THE UNITED STATES OF AMERICA
☐ WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA
(NAME OF STATE _____)
(CITATION OF STATUTE _____)

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention entitled

NFAT-INTERACTING PROTEIN NIP45 AND METHODS OF USE THEREFOR

by inventor(s) Laurie H. Glimcher and Martin R. Hodge

described in

- ☐ the specification filed herewith.
☒ application serial no. 08/755,584, filed November 25, 1996
☐ patent no. _____, issued _____

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization regarding the above identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights in the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

NAME Boston Life Sciences

ADDRESS 31 Newbury Street, Suite 300, Boston, MA 02116

☐ INDIVIDUAL ☒ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING _____

TITLE IN ORGANIZATION OF PERSON SIGNING _____

ADDRESS OF PERSON SIGNING _____

SIGNATURE

DATE

Joyce Brinson, Director
Office for Technology and Trademark Licensing
Harvard University

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Laurie H. Glimcher and
Martin R. Hodge

Serial No.:

Filed:

For: *NFAT-Interacting Protein NIP45 and Methods of
Use Therefor*

Attorney Docket No.: HUI-026DV

Group Art Unit:

Examiner:

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Dear Sir:

Prior to examination, please amend the above-referenced patent application as follows:

In the Specification

At page 1, line 11, please insert --This application is a divisional application of serial No. 08/755,584 filed on November 25, 1996, pending. The contents of the aforementioned application is incorporated by reference.--

At page 1, line 15, before "filed" please insert --08/755,592--

In the Claims:

Please cancel claims 1-25, 37, 38, 44, and 45 without prejudice.

03142511-11545

Please add new claims 46-54.

46. **(New)** A method for identifying a compound that modulates the activity of NIP45, comprising
providing a indicator composition comprising NIP45 activity;
contacting the indicator composition with a test compound; and
determining the effect of the test compound on NIP45 activity in the indicator composition to thereby identify a compound that modulates the activity of NIP45.

47. **(New)** The method of claim 46, wherein the indicator composition comprises an indicator cell, wherein said indicator cell comprises NIP45 and a reporter gene responsive to NIP45.

48. **(New)** The method of claim 47, wherein the indicator cell is a lymphoid cell.

49. **(New)** The method of claim 48, wherein the lymphoid cell is a Th2 cell.

50. **(New)** The method of claim 47, wherein the indicator cell is a yeast cell.

51. **(New)** A method for identifying a compound that modulates an immune response, comprising

providing a indicator composition comprising NIP45 activity;
contacting the indicator composition with a library of test compounds;
selecting from the library of test compounds a compound of interest that modulates the activity of NIP45; and
determining the effect of the compound of interest on an immune response to thereby identify a compound that modulates an immune response.

52. **(New)** The method of claim 51, wherein the effect of the compound of interest on an immune response is determined by determining the effect of the compound on expression of a Th2-associated cytokine gene.

53. **(New)** The method of claim 52, wherein the Th2-associated cytokine gene is an interleukin-4 gene.

09192611, 11698

54. **(New)** The method of claim 51, wherein the effect of the compound of interest on an immune response is determined by determining the effect of the compound on development of T helper type 1 (Th1) or T helper type 2 (Th2) cells.

RECEIVED
JAN 11 2006

REMARKS

Prior to this preliminary amendment, originally filed claims 1-45 were pending. Claims 1-25, 37, 38, 44, and 45 have been canceled. New claims 46-54 have been added. Accordingly, claims 26-36, 39-43, and 46-54 are currently pending. All of the claims as pending after entry of the above amendment are attached as Appendix A.

Support for the new claims 46-54, directed to methods for identifying compounds that modulate the activity of NIP45 or modulate an immune response, can be found in originally filed claims 44-45 and throughout the specification, in particular at, for example, page 27, line 12 through page 30, line 23. Accordingly, no new matter has been added.

Respectfully submitted,



Megan E. Williams
Registration No. 43,270
Agent for Applicants

LAHIVE & COCKFIELD, LLP
28 State Street
Boston, MA 02109
Tel. (617) 227-7400
Dated: November 16, 1998

09192611-111598

NF-AT-INTERACTING PROTEIN NIP45 AND METHODS OF USE THEREFOR

5 **Government Funding**

Work described herein was supported, at least in part, under grant AI37833 awarded by the National Institutes of Health. The U.S. government therefore may have certain rights in this invention.

10 **Related Applications**

This application is related to U.S. Serial No. 08/636,602, entitled "*Methods and Compositions for Regulating T cell Subsets by Modulating Transcription Factor Activity*", filed April 23, 1996, and to a continuation-in-part application thereof, entitled "*Methods for Regulating T cell Subsets by Modulating Transcription Factor Activity*", U.S. Serial No. _____, filed on November 25, 1996 (Attorney Docket No. HUI-021CP), the entire contents of both of which are expressly incorporated herein by reference.

Background of the Invention

CD4+ T helper cells are not a homogeneous population but can be divided on the basis of cytokine secretion into at least two subsets termed T helper type 1 (Th1) and T helper type 2 (Th2) (see *e.g.*, Mosmann, T.R. *et al.* (1986) *J. Immunol.* **136**:2348-2357; Paul, W.E. and Seder, R.A. (1994) *Cell* **76**:241-251; Seder, R.A. and Paul, W.E. (1994) *Ann. Rev. Immunol.* **12**:635-673). Th1 cells secrete interleukin-2 (IL-2) and interferon- γ (IFN- γ) while Th2 cells produce interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-10 (IL-10) and interleukin-13 (IL-13). Both subsets produce cytokines such as tumor necrosis factor (TNF) and granulocyte/macrophage-colony stimulating factor (GM-CSF). In addition to their different pattern of cytokine expression, Th1 and Th2 cells are thought to have differing functional activities. For example, Th1 cells are involved in inducing delayed type hypersensitivity responses, whereas Th2 cells are involved in providing efficient "help" to B lymphocytes and stimulating production of IgG1 and IgE antibodies.

There is now abundant evidence that the ratio of Th1 to Th2 cells is highly relevant to the outcome of a wide array of immunologically-mediated clinical diseases including autoimmune, allergic and infectious diseases. For example, in experimental leishmania infections in mice, animals that are resistant to infection mount predominantly a Th1 response, whereas animals that are susceptible to progressive infection mount predominantly a Th2 response (Heinzel, F.P., *et al.* (1989) *J. Exp. Med.* **169**:59-72; Locksley, R. M. and Scott, P. (1992) *Immunoparasitology Today* **1**:A58-A61). In murine schistosomiasis, a Th1 to Th2 switch is observed coincident with the release of eggs into the tissues by female parasites and is associated with a worsening of the disease condition

(Pearce, E.J., *et al.* (1991) *J. Exp. Med.* **173**:159-166; Grzych, J-M., *et al.* (1991) *J. Immunol.* **141**:1322-1327; Kullberg, M.C., *et al.* (1992) *J. Immunol.* **148**:3264-3270). Many human diseases, including chronic infections (such as with human immunodeficiency virus (HIV) and tuberculosis) and certain metastatic carcinomas, also are characterized by a Th1 to Th2 switch (see *e.g.*, Shearer, G.M. and Clerici, M. (1992) *Prog. Chem. Immunol.* **54**:21-43; Clerici, M and Shearer, G.M. (1993) *Immunology Today* **14**:107-111; Yamamura, M., *et al.* (1993) *J. Clin. Invest.* **91**:1005-1010; Pisa, P., *et al.* (1992) *Proc. Natl. Acad. Sci. USA* **89**:7708-7712; Fauci, A.S. (1988) *Science* **239**:617-623).

Furthermore, certain autoimmune diseases have been shown to be associated with a

predominant Th1 response. For example, patients with rheumatoid arthritis have predominantly Th1 cells in synovial tissue (Simon, A.K., *et al.* (1994) *Proc. Natl. Acad. Sci. USA* **91**:8562-8566) and experimental autoimmune encephalomyelitis (EAE) can be induced by autoreactive Th1 cells (Kuchroo, V.K., *et al.* (1993) *J. Immunol.* **151**:4371-4381).

The ability to alter or manipulate ratios of Th1 and Th2 subsets requires an understanding of the mechanisms by which the differentiation of CD4 T helper precursor cells (Thp), which secrete only IL-2, choose to become Th1 or Th2 effector cells. It is clear that the cytokines themselves are potent Th cell inducers and form an autoregulatory loop (see *e.g.*, Paul, W.E. and Seder, R.A. (1994) *Cell* **76**:241-251; Seder, R.A. and Paul, W.E. (1994) *Ann. Rev. Immunol.* **12**:635-673). Thus, IL-4 promotes the differentiation of Th2 cells while preventing the differentiation of precursors into Th1 cells, while IL-12 and IFN- γ have the opposite effect. One possible means therefore to alter Th1:Th2 ratios is to increase or decrease the level of selected cytokines. Direct administration of cytokines or antibodies to cytokines has been shown to have an effect on certain diseases mediated by either Th1 or Th2 cells. For example, administration of recombinant IL-4 or antibodies to IL-12 ameliorate EAE, a Th1-driven autoimmune disease (see Racke; M.K. *et al.* (1994) *J. Exp. Med.* **180**:1961-1966; and Leonard, J.P. *et al.* (1995) *J. Exp. Med.* **181**:381-386), while anti-IL-4 antibodies cure the Th2-mediated parasitic disease, *Leishmania major* (Sadick, M.D. *et al.* (1990) *J. Exp. Med.* **171**:115-127). However, as therapeutic options, systemic administration of cytokines or antibodies may have unwanted side effects and, accordingly, alternative approaches to manipulating Th1/Th2 subsets are still needed.

While the molecular basis for the tissue-specific expression of T cell cytokines has remained elusive, study of the transcriptional elements of cytokine genes has provided insight into their regulation. Analysis of the IL-4 cytokine promoter, for example, has revealed functionally critical sites for several transcription factors including members of the NF-AT and AP-1 families (Rooney, J.W. *et al.* (1995) *Immunity* **2**:473-483; Szabo, S.J. *et al.* (1993) *Mol. Cell. Biol.* **13**:4793-4805). NF-AT is a multisubunit transcription complex that contains a cyclosporin A sensitive cytoplasmic phosphoprotein and an inducible nuclear component composed of AP-1 family member proteins (Flanagan, W.M. *et al.*

(1991) *Nature* 352:803-807; Jain, J. *et al.* (1992) *Nature* 356:801-804). Purification and cloning of NF-ATp revealed a region of limited sequence identity to the Rel Homology Domain (RHD) of the NFκB family of transcription factors (McCaffrey, P.G. *et al.* (1993) *Science* 262:750-754). Subsequent cloning and sequencing of three related genes, NF-ATc, NF-AT4/x/c3, and NF-AT3/c4 revealed similar domains. NF-AT family members share approximately 70% sequence similarity within this domain and approximately 18% sequence similarity to the RHD of the Rel/NFκB family of transcription factors. Consistent with their very limited sequence similarity in the RHD, there are marked differences in the behavior of NFκB and NF-AT proteins, and much less is known about the pathways that mediate transcriptional regulation of NF-AT target genes. However, considering that NF-AT family members can bind to and transactivate the promoters of multiple cytokine genes including IL-2 and IL-4 (Rooney, J. *et al.* (1995) *Immunity* 2:545-553; Szabo, S.J. *et al.* (1993) *Mol. Cell. Biol.* 13:4793-4805; Flanagan, W.M. *et al.* (1991) *Nature* 352:803-807; Northrop, J.P. *et al.* (1994) *Nature* 369:497), NF-AT proteins are not likely to be directly responsible for mediating Th1- or Th2-specific cytokine transcription.

Most, if not all, NF-AT binding sites in cytokine promoter regulatory regions are accompanied by nearby sites that bind auxiliary transcription factors, usually members of the AP-1 family. It has been shown that NF-AT and AP-1 proteins bind coordinately and cooperatively and are required for full activity of the IL-2 and IL-4 promoters. Different AP-1 proteins, specifically c-Jun, c-Fos, Fra-1, Fra-2, Jun B and Jun D, have been shown to bind to these sites (Rao, A. *et al.* (1994) *Immunol. Today* 15:274-281; Jain, J. *et al.* (1993) *Nature* 365:352-355; Boise, L.H. *et al.* (1993) *Mol. Cell. Biol.* 13:1911-1919; Rooney, J. *et al.* (1995) *Immunity* 2:545-553; Rooney, J. *et al.* (1995) *Mol. Cell. Biol.* 15:6299-6310). However, none of these AP-1 proteins is expressed in a Th1- or Th2-specific manner and there is no evidence for the differential recruitment of AP-1 family members to the IL-2 or IL-4 composite sites (Rooney, J. *et al.* (1995) *Mol. Cell. Biol.* 15:6299-6310). Thus, neither NF-AT proteins nor the AP-1 family members c-Jun, c-Fos, Fra-1, Fra-2, Jun B and Jun D can account for the tissue-specific transcription of IL-4 in Th2 cells.

In the related co-pending application U.S. Serial No. 08/636,602, we have provided evidence that the selective expression of the proto-oncogene c-maf in Th2 cells is responsible for tissue-specific IL-4 expression. Interestingly, c-Maf acts in synergy with NF-AT proteins to transactivate the IL-4 promoter. This is consistent with previous data that the inducible expression of multiple cytokine genes and cell surface proteins following T cell receptor stimulation requires members of the NF-AT transcription factor family (Rooney, J.W. *et al.* (1995) *Immunity* 2:473-483; Cockerill, P.N. *et al.* (1995) *Mol. Cell. Biol.* 15:2071-2079; Goldfeld, A.E. *et al.* (1993) *J. Exp. Med.* 178:1365-1379; Shaw, J.P. *et al.* (1988) *Science* 241:202-205). However, it was unknown, prior to the present invention, whether additional proteins exist that act in concert with known transcriptional activators, such as NF-AT and c-Maf, to activate cytokine gene expression.

Summary of the Invention

A 45 kDa protein, termed NIP45, that interacts with members of the NF-AT family of proteins has now been isolated and characterized. NIP45 was isolated based upon its ability to interact with the Rel Homology Domain (RHD) of NF-AT. Furthermore, NIP45 has been shown to synergize with NF-AT and c-Maf to stimulate cytokine gene expression. This invention pertains to isolated compositions of NIP45 protein and isolated nucleic acid sequences encoding NIP45, other compositions related thereto and methods of use thereof. The amino acid sequence of NIP45 protein has been determined (shown in SEQ ID NO: 2) and a cDNA encoding NIP45 protein has been isolated (the nucleotide sequence of which is shown in SEQ ID NO: 1).

One aspect of the invention pertains to isolated nucleic acid molecules encoding NIP45, or fragments thereof. In one embodiment, the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding NIP45 protein. In another embodiment, the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO: 2 and interacts with the Rel Homology Domain of an NF-AT family protein. In yet another embodiment, the invention provides an isolated nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1. In yet another embodiment, the invention provides an isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1. In still other embodiments, the invention provides an isolated nucleic acid molecule encoding the amino acid sequence of SEQ ID NO: 2. Isolated nucleic acid molecules encoding NIP45 fusion proteins and isolated antisense nucleic acid molecules are also encompassed by the invention.

Another aspect of the invention pertains to vectors, such as recombinant expression vectors, containing a nucleic acid molecule of the invention and host cells into which such vectors have been introduced. In one embodiment, such a host cell is used to produce NIP45 protein by culturing the host cell in a suitable medium. If desired, NIP45 protein can be then isolated from the host cell or the medium.

Still another aspect of the invention pertains to isolated NIP45 proteins, or portions thereof. In one embodiment, the invention provides an isolated NIP45 protein, or a portion thereof that interacts with an NF-AT family protein. In yet another embodiment, the invention provides an isolated protein which comprises an amino acid sequence homologous to the amino acid sequence of SEQ ID NO: 2 and that interacts with an NF-AT family protein. NIP45 fusion proteins are also encompassed by the invention.

The NIP45 proteins of the invention, or fragments thereof, can be used to prepare anti-NIP45 antibodies. Accordingly, the invention further provides an antibody that

specifically binds NIP45 protein. In one embodiment, the antibody is monoclonal. In another embodiment, the antibody is labeled with a detectable substance.

The NIP45-encoding nucleic acid molecules of the invention can be used to prepare nonhuman transgenic animals that contain cells carrying a transgene encoding NIP45 protein or a portion of NIP45 protein. Accordingly, such transgenic animals are also provided by the invention. In one embodiment, the NIP45 transgene carried by the transgenic animal alters an endogenous gene encoding endogenous NIP45 protein (*e.g.*, a homologous recombinant animal).

Another aspect of the invention pertains to methods for detecting the presence of NIP45 protein or mRNA in a biological sample. To detect NIP45 protein or mRNA, the biological sample is contacted with an agent capable of detecting NIP45 protein (such as a labeled anti-NIP45 antibody) or NIP45 mRNA (such as a labeled nucleic acid probe capable of hybridizing to NIP45 mRNA) such that the presence of NIP45 protein or mRNA is detected in the biological sample.

Still another aspect of the invention pertains to methods for identifying compounds that modulate the activity or expression of NIP45 and methods for identifying compounds that modulate an interaction between NIP45 and an NF-AT family protein. Screening methods for identifying proteins that interact with NIP45 are also encompassed by the invention.

Brief Description of the Drawings

Figure 1 is photograph of yeast colonies, in triplicate, transformed with the NIP45 plasmid and either NF-ATp-RHD as "bait" or control baits, Max, CDK2 or pEG202, together with the LacZ reporter plasmid pSH18, indicating that only those colonies containing the NIP45 plasmid and the NF-ATp-RHD bait expressed the LacZ reporter gene.

Figure 2 is a photograph of an immunoprecipitation/Western blot experiment demonstrating that NIP45 and NF-ATp interact in HepG2 cells.

Figure 3 is a schematic diagram comparing the structures of the original NIP45 cDNA clone isolated from the yeast two-hybrid screen (top) and the longest NIP45 cDNA clone isolated from a D10.G4 lambda zap II library (bottom).

Figure 4 depicts the nucleotide and predicted amino acid sequences of the original NIP45 cDNA isolate.

Figure 5 depicts the hydrophobicity plot of the NIP45 cDNA.

Figure 6 is a photograph of an RNA blot analysis of NIP45 transcript levels in various tissues.

Figure 7A is a photograph of immunofluorescence analysis of BHK cells transfected with an expression construct encoding an HA-epitope tagged NIP45 protein and

probed with a monoclonal antibody specific for the HA peptide as the primary antibody and an indocarbocyanine labelled goat anti-mouse secondary reagent.

Figure 7B is a photograph of the same cells depicted in Figure 7A counterstained with the DNA staining dye Hoechst 33258.

5 Figure 7C is a photograph of immunofluorescence analysis of unstimulated BHK cells transfected with an expression construct encoding NF-AT4 and probed with an anti-NF-AT4 specific antibody as the primary antibody and an indocarbocyanine labelled goat anti-mouse secondary reagent.

10 Figure 7D is a photograph of the same cells depicted in Figure 7C counterstained with the DNA staining dye Hoechst 33258.

Figure 7E is a photograph of immunofluorescence analysis of ionomycin-treated BHK cells transfected with an expression construct encoding NF-AT4 and probed with an anti-NF-AT4 specific antibody as the primary antibody and an indocarbocyanine labelled goat anti-mouse secondary reagent.

15 Figure 7F is a photograph of the same cells depicted in Figure 7D counterstained with the DNA staining dye Hoechst 33258.

Figure 8 is a photograph of CAT assay results (left) and a bar graph quantitating the relative fold induction of CAT activity (right) in HepG2 cells transfected with a 3X NF-AT-CAT reporter gene construct (containing three NF-AT binding sites) and either a control expression plasmid or an NF-AT expression plasmid (NF-ATp, NF-ATc, NF-AT3 or NF-AT4), alone (-) or in combination with a NIP45 expression plasmid (+).

20 Figure 9 is a photograph of CAT assay results (left) and a bar graph quantitating the relative fold induction of CAT activity (right) in HepG2 cells transfected with an IL-4-CAT reporter gene construct (extending to -732 bp of the IL-4 promoter) and combinations of
25 NF-ATp, NIP45 and/or c-Maf expression constructs, as indicated.

Figure 10 is a bar graph depicting the level of IL-4 (in pg/ml) in the supernatants of M12 B lymphoma cells transiently cotransfected with expression plasmids for NF-ATp, c-Maf and a pCI vector control (top bar) or expression plasmids for NF-ATp, c-Maf and NIP45 (bottom bar).

30

Detailed Description of the Invention

This invention pertains to NF-AT Interacting Protein 45 (NIP45), a 45 kDa protein that interacts with NF-AT proteins. A cDNA encoding NIP45 was isolated based upon the interaction of NIP45 with the RHD of NF-ATp using a two-hybrid interaction trap assay in yeast (see Example 1). Coimmunoprecipitation experiments demonstrated that NIP45 and NF-AT interact *in vivo* in mammalian cells (see Example 2). The cDNA encoding NIP45 has been sequenced and characterized (see Example 3). Examination of the tissue expression pattern of NIP45 mRNA revealed that the NIP45 transcript is preferentially expressed in spleen, thymus and testis (see Example 4). Subcellular localization studies

demonstrated that NIP45 protein is evenly distributed throughout the cell nucleus (see Example 5). Functional studies showed that NIP45 synergizes with NF-AT to stimulate transcription from promoters containing NF-AT binding sites and, moreover, synergizes with NF-AT and c-Maf to stimulate transcription from the IL-4 promoter (see Example 6).

- 5 Moreover, NIP45, NF-AT and c-Maf can act in concert to induce expression of the endogenous IL-4 gene in cells that do not normally express IL-4 (*e.g.*, B cells.) (see Example 7).

So that the invention may be more readily understood, certain terms are first defined.

- 10 As used herein, the term "NF-AT family protein" (also referred to interchangeably as simple "NF-AT") refers to the family of Nuclear Factors of Activated T cell transcription factors, including NF-ATp, NF-ATc, NF-AT4/x/c3 and NF-AT3/c4.

- As used herein the term "Rel Homology Domain of an NF-AT family protein" (abbreviated as RHD domain) refers to a domain within NF-AT family proteins having
15 approximately 70% sequence similarity within the RHD of the Rel/NFκB family of transcription factors.

- As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (*e.g.*, cDNA or genomic DNA) and RNA molecules (*e.g.*, mRNA). The nucleic acid molecule may be single-stranded or double-stranded, but preferably is double-stranded
20 DNA.

- An used herein, an "isolated nucleic acid molecule" refers to a nucleic acid molecule that is free of gene sequences which naturally flank the nucleic acid in the genomic DNA of the organism from which the nucleic acid is derived (*i.e.*, gene sequences that are located adjacent to the isolated nucleic molecule in the genomic DNA of the
25 organism from which the nucleic acid is derived). For example, in various embodiments, the isolated NIP45 nucleic acid molecule may contain less than about 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, may be free of other cellular
30 material.

- As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60 % homologous to each other typically remain hybridized to each other. Preferably, the conditions are such that at least sequences at least 65 %, more preferably at least 70 %, and even more preferably at least 75 % homologous to each other typically remain
35 hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization

conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C.

As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (*e.g.*, encodes a natural protein).

As used herein, an "antisense" nucleic acid comprises a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a protein, *e.g.*, complementary to the coding strand of a double-stranded cDNA molecule, complementary to an mRNA sequence or complementary to the coding strand of a gene. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid.

As used herein, the term "coding region" refers to regions of a nucleotide sequence comprising codons which are translated into amino acid residues, whereas the term "noncoding region" refers to regions of a nucleotide sequence that are not translated into amino acids (*e.g.*, 5' and 3' untranslated regions).

As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments may be ligated. Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" or simply "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" may be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

As used herein, the term "host cell" is intended to refer to a cell into which a nucleic acid of the invention, such as a recombinant expression vector of the invention, has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It should be understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

As used herein, a "transgenic animal" refers to a non-human animal, preferably a mammal, more preferably a mouse, in which one or more of the cells of the animal includes a "transgene". The term "transgene" refers to exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, for example directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal.

As used herein, a "homologous recombinant animal" refers to a type of transgenic non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, *e.g.*, an embryonic cell of the animal, prior to development of the animal.

As used herein, an "isolated protein" refers to a protein that is substantially free of cellular material or culture medium when isolated from cells or produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized.

As used herein, the term "antibody" is intended to include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, *i.e.*, molecules that contain an antigen binding site which specifically binds (immunoreacts with) an antigen, such as Fab and F(ab')₂ fragments. The terms "monoclonal antibody" and "monoclonal antibody composition", as used herein, refer to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of an antigen. A monoclonal antibody composition thus typically displays a single binding affinity for a particular antigen with which it immunoreacts.

Various aspects of the invention are described in further detail in the following subsections:

I. Isolated Nucleic Acid Molecules

One aspect of the invention pertains to isolated nucleic acid molecules that encode NIP45, or fragments thereof. In a preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO: 1. The sequence of SEQ ID NO: 1 corresponds to the mouse NIP45 cDNA. This cDNA comprises sequences encoding the NIP45 protein (*i.e.*, "the coding region", from nucleotides 13-1248), as well as 5' untranslated sequences (nucleotides 1-12) and 3' untranslated sequences (nucleotides 1249-1946). Alternatively, the nucleic acid molecule may comprise only the coding region of SEQ ID NO: 1 (*i.e.*, nucleotides 13-1248).

Moreover, the nucleic acid molecule of the invention can comprise only a portion of the coding region of SEQ ID NO: 1, for example a fragment encoding a biologically active portion of NIP45. The term "biologically active portion of NIP45" is intended to include

portions of NIP45 that retain the ability to interact with the RHD of NF-AT family proteins. The ability of portions of NIP45 to interact with an NF-AT RHD can be determined in standard *in vitro* interaction assays, for example using a NF-AT RHD fusion protein. Nucleic acid fragments encoding biologically active portions of NIP45 can be prepared by isolating a portion of SEQ ID NO: 1, expressing the encoded portion of NIP45 protein or peptide (e.g., by recombinant expression in a host cell) and assessing the ability of the portion to interact with NF-AT, in particular the NF-AT RHD, for example using a glutathione-S-transferase (GST)-NF-AT RHD fusion protein.

The invention further encompasses nucleic acid molecules that differ from SEQ ID NO: 1 (and fragments thereof) due to degeneracy of the genetic code and thus encode the same NIP45 protein as that encoded by SEQ ID NO: 1. Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID NO: 2. Moreover, the invention encompasses nucleic acid molecules that encode portions of SEQ ID NO: 2, such as biologically active portions thereof.

A nucleic acid molecule having the nucleotide sequence of SEQ ID NO: 1, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein. For example, a NIP45 cDNA can be isolated from a cDNA library using all or portion of SEQ ID NO: 1 as a hybridization probe and standard hybridization techniques (e.g., as described in Sambrook, J., *et al. Molecular Cloning: A Laboratory Manual*, 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989). Moreover, a nucleic acid molecule encompassing all or a portion of SEQ ID NO: 1 can be isolated by the polymerase chain reaction using oligonucleotide primers designed based upon the sequence of SEQ ID NO: 1. For example, mRNA can be isolated from cells (e.g., by the guanidinium-thiocyanate extraction procedure of Chirgwin *et al.* (1979) *Biochemistry* 18: 5294-5299) and cDNA can be prepared using reverse transcriptase (e.g., Moloney MLV reverse transcriptase, available from Gibco/BRL, Bethesda, MD; or AMV reverse transcriptase, available from Seikagaku America, Inc., St. Petersburg, FL). Synthetic oligonucleotide primers for PCR amplification can be designed based upon the nucleotide sequence shown in SEQ ID NO: 1. A nucleic acid of the invention can be amplified using cDNA or, alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to a NIP45 nucleotide sequence can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.

In addition to the NIP45 nucleotide sequence shown in SEQ ID NO: 1, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of NIP45 may exist within a population. Such genetic

polymorphism in the NIP45 gene may exist among individuals within a population due to natural allelic variation. Such natural allelic variations can typically result in 1-5 % variance in the nucleotide sequence of the a gene. Any and all such nucleotide variations and resulting amino acid polymorphisms in NIP45 that are the result of natural allelic
5 variation and that do not alter the functional activity of NIP45 are intended to be within the scope of the invention. Moreover, nucleic acid molecules encoding NIP45 proteins from other species, and thus which have a nucleotide sequence that differs from the mouse sequence of SEQ ID NO: 1 but that is related to the mouse sequence, are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic
10 variants and human and other mammalian homologues of the mouse NIP45 cDNA of the invention can be isolated based on their homology to the mouse NIP45 nucleic acid molecule disclosed herein using the mouse cDNA, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. Accordingly, in another embodiment, an isolated nucleic acid molecule of the
15 invention hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1. In certain embodiment, the nucleic acid is at least 15, 30, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or 1500 nucleotides in length. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NO: 1 corresponds to a naturally-occurring
20 nucleic acid molecule. In on embodiment, the nucleic acid encodes natural human NIP45 protein. In another embodiment, the nucleic acid molecule encodes a murine NIP45 protein, such as mouse NIP45 protein.

In addition to naturally-occurring allelic variants of the NIP45 sequence that may exist in the population, the skilled artisan will further appreciate that changes may be
25 introduced by mutation into the nucleotide sequence of SEQ ID NO: 1, thereby leading to changes in the amino acid sequence of the encoded protein, without altering the functional activity of the NIP45 protein. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues may be made in the sequence of SEQ ID NO: 1. A "non-essential" amino acid residue is a residue that can be altered from the
30 wild-type sequence of NIP45 (e.g., the sequence of SEQ ID NO: 2) without altering the functional activity of NIP45, such as its ability to interact with an NF-AT RHD or its ability to synergize with NF-AT and c-Maf in stimulating gene transcription, whereas an "essential" amino acid residue is required for functional activity.

Accordingly, another aspect of the invention pertains to nucleic acid molecules
35 encoding NIP45 proteins that contain changes in amino acid residues that are not essential for NIP45 activity. Such NIP45 proteins differ in amino acid sequence from SEQ ID NO: 2 yet retain NIP45 activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least 60 % homologous to the amino acid sequence of SEQ ID NO: 2 and

interacts with the RHD of an NF-AT family protein. Preferably, the protein encoded by the nucleic acid molecule is at least 70 % homologous to SEQ ID NO: 2, more preferably at least 80 % homologous to SEQ ID NO: 2, even more preferably at least 90 % homologous to SEQ ID NO: 2, and most preferably at least 95 % homologous to SEQ ID NO: 2.

To determine the percent homology of two amino acid sequences (e.g., SEQ ID NO: 2 and a mutant form thereof), the sequences are aligned for optimal comparison purposes (e.g., gaps may be introduced in the sequence of one protein for optimal alignment with the other protein). The amino acid residues at corresponding amino acid positions are then compared. When a position in one sequence (e.g., SEQ ID NO: 2) is occupied by the same amino acid residue as the corresponding position in the other sequence (e.g., a mutant form of NIP45), then the molecules are homologous at that position (i.e., as used herein amino acid "homology" is equivalent to amino acid "identity"). The percent homology between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % homology = # of identical positions/total # of positions x 100).

An isolated nucleic acid molecule encoding a NIP45 protein homologous to the protein of SEQ ID NO: 2 can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO: 1 such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced into SEQ ID NO: 1 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, an amino acid residue in NIP45 protein is preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a NIP45 coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for their ability to interact with an NF-AT RHD (e.g., using a GST-NF-AT-RHD fusion protein) to identify mutants that retain NF-AT-interacting ability. Following mutagenesis of SEQ ID NO: 1, the encoded mutant protein can be expressed recombinantly in a host cell and the ability of the mutant protein to interact with NF-AT can be determined using an *in vitro* interaction assay. For example, a recombinant NIP45 protein (e.g., a mutated or truncated form of SEQ ID NO: 2) can be radiolabeled and incubated with a GST-NF-AT RHD fusion protein.

Glutathione-sepharose beads are then added to the mixture to precipitate the NIP45-GST-NF-AT RHD complex, if such a complex is formed. After washing the beads to remove non-specific binding, the amount of radioactive protein associated with the beads is determined and compared to the amount of radioactive protein remaining in the eluate to thereby determine whether the NIP45 protein is capable of interacting with the RHD of NF-AT.

Another aspect of the invention pertains to isolated nucleic acid molecules that are antisense to the coding strand of a NIP45 mRNA or gene. An antisense nucleic acid of the invention can be complementary to an entire NIP45 coding strand, or to only a portion thereof. In one embodiment, an antisense nucleic acid molecule is antisense to a coding region of the coding strand of a nucleotide sequence encoding NIP45 (*e.g.*, the entire coding region of SEQ ID NO: 1 comprises nucleotides 13-1248). In another embodiment, the antisense nucleic acid molecule is antisense to a noncoding region of the coding strand of a nucleotide sequence encoding NIP45. In certain embodiments, an antisense nucleic acid of the invention is at least 15, 30, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or 1500 nucleotides in length.

Given the coding strand sequences encoding NIP45 disclosed herein (*e.g.*, SEQ ID NO: 1), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule may be complementary to the entire coding region of NIP45 mRNA, or alternatively can be an oligonucleotide which is antisense to only a portion of the coding or noncoding region of NIP45 mRNA. For example, the antisense oligonucleotide may be complementary to the region surrounding the translation start site of NIP45 mRNA. An antisense oligonucleotide can be, for example, about 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, *e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

In another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. A ribozyme having specificity for a NIP45-encoding nucleic acid

can be designed based upon the nucleotide sequence of a NIP45 cDNA disclosed herein (i.e., SEQ ID NO: 1). For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the base sequence of the active site is complementary to the base sequence to be cleaved in a NIP45-encoding mRNA. See for example Cech *et al.* U.S. Patent No. 4,987,071; and Cech *et al.* U.S. Patent No. 5,116,742. Alternatively, NIP45 mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See for example Bartel, D. and Szostak, J.W. (1993) *Science* 261: 1411-1418.

Yet another aspect of the invention pertains to isolated nucleic acid molecules encoding NIP45 fusion proteins. Such nucleic acid molecules, comprising at least a first nucleotide sequence encoding a NIP45 protein, polypeptide or peptide operatively linked to a second nucleotide sequence encoding a non-NIP45 protein, polypeptide or peptide, can be prepared by standard recombinant DNA techniques. NIP45 fusion proteins are described in further detail below in subsection III.

II. Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably recombinant expression vectors, containing a nucleic acid encoding NIP45 (or a portion thereof). The expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector may depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, *etc.* The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., NIP45 proteins, mutant forms of NIP45 proteins, NIP45 fusion proteins and the like).

The recombinant expression vectors of the invention can be designed for expression of NIP45 protein in prokaryotic or eukaryotic cells. For example, NIP45 can be expressed in bacterial cells such as *E. coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, *Gene*

5 *Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector may be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either
10 fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion
15 expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D.B. and Johnson, K.S. (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann *et al.*, (1988) *Gene* 69:301-315) and pET 11d (Studier *et al.*, *Gene Expression*
25 *Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 60-89). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host
30 strains BL21(DE3) or HMS174(DE3) from a resident λ prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter.

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., *Gene Expression Technology: Methods in Enzymology*
35 185, Academic Press, San Diego, California (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada *et al.*, (1992) *Nuc. Acids Res.* 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the NIP45 expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1 (Baldari, *et al.*, (1987) *EMBO J.* 6:229-234), pMFa (Kurjan and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz *et al.*, (1987) *Gene* 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, CA).

Alternatively, NIP45 can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (*e.g.*, Sf9 cells) include the pAc series (Smith *et al.*, (1983) *Mol. Cell Biol.* 3:2156-2165) and the pVL series (Lucklow, V.A., and Summers, M.D., (1989) *Virology* 170:31-39).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pMex-NeoI, pCDM8 (Seed, B., (1987) *Nature* 329:840) and pMT2PC (Kaufman *et al.* (1987), *EMBO J.* 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (*e.g.*, tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include lymphoid-specific promoters (Calame and Eaton (1988) *Adv. Immunol.* 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) *EMBO J.* 8:729-733) and immunoglobulins (Banerji *et al.* (1983) *Cell* 33:729-740; Queen and Baltimore (1983) *Cell* 33:741-748), the albumin promoter (liver-specific; Pinkert *et al.* (1987) *Genes Dev.* 1:268-277), neuron-specific promoters (*e.g.*, the neurofilament promoter; Byrne and Ruddle (1989) *Proc. Natl. Acad. Sci. USA* 86:5473-5477), pancreas-specific promoters (Edlund *et al.* (1985) *Science* 230:912-916), and mammary gland-specific promoters (*e.g.*, milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) *Science* 249:374-379) and the α -fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev.* 3:537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to NIP45 mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or

regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub, H. *et al.*, Antisense RNA as a molecular tool for genetic analysis, *Reviews - Trends in Genetics*, Vol. 1(1) 1986.

Another aspect of the invention pertains to recombinant host cells into which a vector, preferably a recombinant expression vector, of the invention has been introduced. A host cell may be any prokaryotic or eukaryotic cell. For example, NIP45 protein may be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art. Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (*e.g.*, DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook *et al.* (*Molecular Cloning: A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (*e.g.*, resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker may be introduced into a host cell on the same vector as that encoding NIP45 or may be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (*e.g.*, cells that have incorporated the selectable marker gene will survive, while the other cells die).

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (*i.e.*, express) NIP45 protein. Accordingly, the invention further provides methods for producing NIP45 protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding NIP45 has been introduced) in a suitable medium until NIP45 is produced. In another embodiment, the method further comprises

isolating NIP45 from the medium or the host cell. In its native form NIP45 protein is an intracellular protein and, accordingly, recombinant NIP45 protein can be expressed intracellularly in a recombinant host cell and then isolated from the host cell, e.g., by lysing the host cell and recovering the recombinant NIP45 protein from the lysate. Alternatively, 5 recombinant NIP45 protein can be prepared as an extracellular protein by operatively linking a heterologous signal sequence to the amino-terminus of the protein such that the protein is secreted from the host cells. In this case, recombinant NIP45 protein can be recovered from the culture medium in which the cells are cultured.

Certain host cells of the invention can also be used to produce nonhuman transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which NIP45-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous NIP45 sequences have been introduced into their genome or homologous recombinant animals in which endogenous NIP45 sequences have been altered. Such animals are useful 10 for studying the function and/or activity of NIP45 and for identifying and/or evaluating modulators of NIP45 activity. Accordingly, another aspect of the invention pertains to nonhuman transgenic animals which contain cells carrying a transgene encoding a NIP45 protein or a portion of a NIP45 protein. In a subembodiment, of the transgenic animals of the invention, the transgene alters an endogenous gene encoding an endogenous NIP45 20 protein (e.g., homologous recombinant animals in which the endogenous NIP45 gene has been functionally disrupted or "knocked out", or the nucleotide sequence of the endogenous NIP45 gene has been mutated or the transcriptional regulatory region of the endogenous NIP45 gene has been altered).

A transgenic animal of the invention can be created by introducing NIP45-encoding 25 nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The mouse NIP45 cDNA sequence of SEQ ID NO: 1 can be introduced as a transgene into the genome of a non-human animal (e.g., a mouse). Alternatively, a mammalian homologue of the mouse NIP45 gene, such as a human NIP45 gene, can be isolated based on hybridization to the mouse NIP45 cDNA and used as a transgene. Intronic sequences and polyadenylation 30 signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to the NIP45 transgene to direct expression of NIP45 protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such 35 as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, both by Leder *et al.*, U.S. Patent No. 4,873,191 by Wagner *et al.* and in Hogan, B., *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence

of the NIP45 transgene in its genome and/or expression of NIP45 mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding NIP45 can further be bred to other transgenic animals carrying other transgenes.

To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a NIP45 gene into which a deletion, addition or substitution has been introduced to thereby alter, *e.g.*, functionally disrupt, the endogenous NIP45 gene. The NIP45 gene preferably is a mouse NIP45 gene. For example, a mouse NIP45 gene can be isolated from a mouse genomic DNA library using the mouse NIP45 cDNA of SEQ ID NO: 1 as a probe. The mouse NIP45 gene then can be used to construct a homologous recombination vector suitable for altering an endogenous NIP45 gene in the mouse genome. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous NIP45 gene is functionally disrupted (*i.e.*, no longer encodes a functional protein; also referred to as a "knock out" vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous NIP45 gene is mutated or otherwise altered but still encodes functional protein (*e.g.*, the upstream regulatory region can be altered to thereby alter the expression of the endogenous NIP45 protein). In the homologous recombination vector, the altered portion of the NIP45 gene is flanked at its 5' and 3' ends by additional nucleic acid of the NIP45 gene to allow for homologous recombination to occur between the exogenous NIP45 gene carried by the vector and an endogenous NIP45 gene in an embryonic stem cell. The additional flanking NIP45 nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector (see *e.g.*, Thomas, K.R. and Capecchi, M. R. (1987) *Cell* 51:503 for a description of homologous recombination vectors). The vector is introduced into an embryonic stem cell line (*e.g.*, by electroporation) and cells in which the introduced NIP45 gene has homologously recombined with the endogenous NIP45 gene are selected (see *e.g.*, Li, E. *et al.* (1992) *Cell* 69:915). The selected cells are then injected into a blastocyst of an animal (*e.g.*, a mouse) to form aggregation chimeras (see *e.g.*, Bradley, A. in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E.J. Robertson, ed. (IRL, Oxford, 1987) pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, A. (1991) *Current Opinion in Biotechnology* 2:823-829 and in PCT International Publication Nos.: WO 90/11354 by Le Mouellec *et al.*; WO 91/01140 by Smithies *et al.*; WO 92/0968 by Zijlstra *et al.*; and WO 93/04169 by Berns *et al.*

III. Isolated NIP45 Proteins and Anti-NIP45 Antibodies

Another aspect of the invention pertains to isolated NIP45 proteins, and portions thereof, such as biologically active portions, as well as peptide fragments suitable as immunogens to raise anti-NIP45 antibodies. In one embodiment, the invention provides an isolated preparation of NIP45 protein. Preferably, the NIP45 protein has an amino acid sequence shown in SEQ ID NO: 2. In other embodiments, the NIP45 protein is substantially homologous to SEQ ID NO: 2 and retains the functional activity of the protein of SEQ ID NO: 2 yet differs in amino acid sequence due to natural allelic variation or mutagenesis, or is a mammalian homologue of the protein of SEQ ID NO: 2 (e.g., a human homologue), as described in detail in subsection I above. Accordingly, in another embodiment, the NIP45 protein is a protein which comprises an amino acid sequence at least 60 % homologous to the amino acid sequence of SEQ ID NO: 2 and that interacts with the RHD of an NF-AT family protein. Preferably, the protein is at least 70 % homologous to SEQ ID NO: 2, more preferably at least 80 % homologous to SEQ ID NO: 2, even more preferably at least 90 % homologous to SEQ ID NO: 2, and most preferably at least 95 % homologous to SEQ ID NO: 2.

In other embodiments, the invention provides isolated portions of the NIP45 protein. For example, the invention further encompasses a portion of a NIP45 protein that interacts with NF-AT. As demonstrated in the examples, NIP45 protein interacts with the RHD of NF-AT. An *in vitro* interaction assay (such as that described above in subsection I utilizing a GST-NF-AT RHD fusion protein) can be used to determine the ability of NIP45 peptide fragments to interact with the NF-AT Rel Homology Domain to thereby identify peptide fragments that interact with NF-AT.

NIP45 proteins are preferably produced by recombinant DNA techniques. For example, a nucleic acid molecule encoding the protein is cloned into an expression vector (as described above), the expression vector is introduced into a host cell (as described above) and the NIP45 protein is expressed in the host cell. The NIP45 protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Alternative to recombinant expression, a NIP45 polypeptide can be synthesized chemically using standard peptide synthesis techniques. Moreover, native NIP45 protein can be isolated from cells (e.g., from T cells), for example by immunoprecipitation using an anti-NIP45 antibody.

The invention also provides NIP45 fusion proteins. As used herein, a NIP45 "fusion protein" comprises a NIP45 polypeptide operatively linked to a non-NIP45 polypeptide. A "NIP45 polypeptide" refers to a polypeptide having an amino acid sequence corresponding to NIP45 protein, or a peptide fragment thereof, whereas a "non-NIP45 polypeptide" refers to a polypeptide having an amino acid sequence corresponding to another protein. Within the fusion protein, the term "operatively linked" is intended to

indicate that the NIP45 polypeptide and the non-NIP45 polypeptide are fused in-frame to each other. The non-NIP45 polypeptide may be fused to the N-terminus or C-terminus of the NIP45 polypeptide. For example, in one embodiment, the fusion protein is a GST-NIP45 fusion protein in which the NIP45 sequences are fused to the C-terminus of the GST sequences. In another embodiment, the fusion protein is a NIP45-HA fusion protein in which the NIP45 nucleotide sequence is inserted in to the pCEP4-HA vector (Herrscher, R.F. *et al.* (1995) *Genes Dev.* 9:3067-3082) such that the NIP45 sequences are fused in frame to an influenza hemagglutinin epitope tag. Such fusion proteins can facilitate the purification of recombinant NIP45.

Preferably, a NIP45 fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel *et al.* John Wiley & Sons: 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (*e.g.*, a GST polypeptide or an HA epitope tag). A NIP45-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the NIP45 protein.

An isolated NIP45 protein, or fragment thereof, can be used as an immunogen to generate antibodies that bind NIP45 using standard techniques for polyclonal and monoclonal antibody preparation. The NIP45 protein can be used to generate antibodies or, alternatively, an antigenic peptide fragment of NIP45 can be used as the immunogen. An antigenic peptide fragment of NIP45 typically comprises at least 8 amino acid residues of the amino acid sequence shown in SEQ ID NO: 2 and encompasses an epitope of NIP45 such that an antibody raised against the peptide forms a specific immune complex with NIP45. Preferably, the antigenic peptide comprises at least 10 amino acid residues, more preferably at least 15 amino acid residues, even more preferably at least 20 amino acid residues, and most preferably at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of NIP45 that are located on the surface of the protein, *e.g.*, hydrophilic regions. A hydrophobicity analysis of the NIP45 protein sequence of SEQ ID NO: 2 is shown in Figure 5.

A NIP45 immunogen typically is used to prepare antibodies by immunizing a suitable subject, (e.g., rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for examples, recombinantly expressed NIP45 protein or a chemically synthesized NIP45 peptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent. Immunization of a suitable subject with an immunogenic NIP45 preparation induces a polyclonal anti-NIP45 antibody response.

Accordingly, another aspect of the invention pertains to anti-NIP45 antibodies. Polyclonal anti-NIP45 antibodies can be prepared as described above by immunizing a suitable subject with a NIP45 immunogen. The anti-NIP45 antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized NIP45. If desired, the antibody molecules directed against NIP45 can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as protein A chromatography to obtain the IgG fraction. At an appropriate time after immunization, e.g., when the anti-NIP45 antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975, *Nature* 256:495-497) (see also, Brown *et al.* (1981) *J. Immunol.* 127:539-46; Brown *et al.* (1980) *J Biol Chem* 255:4980-83; Yeh *et al.* (1976) *PNAS* 76:2927-31; and Yeh *et al.* (1982) *Int. J. Cancer* 29:269-75), the more recent human B cell hybridoma technique (Kozbor *et al.* (1983) *Immunol Today* 4:72), the EBV-hybridoma technique (Cole *et al.* (1985), *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96) or trioma techniques. The technology for producing monoclonal antibody hybridomas is well known (see generally R. H. Kenneth, in *Monoclonal Antibodies: A New Dimension In Biological Analyses*, Plenum Publishing Corp., New York, New York (1980); E. A. Lerner (1981) *Yale J. Biol. Med.*, 54:387-402; M. L. Gefter *et al.* (1977) *Somatic Cell Genet.*, 3:231-36). Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with a NIP45 immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds NIP45.

Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating an anti-NIP45 monoclonal antibody (see, e.g., G. Galfre *et al.* (1977) *Nature* 266:55052; Gefter *et al.* (1977) *Somatic Cell Genet.*, cited *supra*; Lerner, *Yale J. Biol. Med.*, cited *supra*; Kenneth, *Monoclonal Antibodies*, cited *supra*). Moreover, the ordinary skilled worker will appreciate that there are many variations of such methods which also would be useful. Typically, the immortal cell line (e.g., a myeloma cell line) is derived from the same mammalian species as the lymphocytes. For example, murine hybridomas can be made by fusing lymphocytes

from a mouse immunized with an immunogenic preparation of the present invention with an immortalized mouse cell line. Preferred immortal cell lines are mouse myeloma cell lines that are sensitive to culture medium containing hypoxanthine, aminopterin and thymidine ("HAT medium"). Any of a number of myeloma cell lines may be used as a fusion partner according to standard techniques, e.g., the P3-NS1/1-Ag4-1, P3-x63-Ag8.653 or Sp2/O-Ag14 myeloma lines. These myeloma lines are available from the American Type Culture Collection (ATCC), Rockville, Md. Typically, HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol ("PEG"). Hybridoma cells resulting from the fusion are then selected using HAT medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days because they are not transformed). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind NIP45, e.g., using a standard ELISA assay.

Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal anti-NIP45 antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with NIP45 to thereby isolate immunoglobulin library members that bind NIP45. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia *Recombinant Phage Antibody System*, Catalog No. 27-9400-01; and the Stratagene *SurfZAP™ Phage Display Kit*, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, Ladner *et al.* U.S. Patent No. 5,223,409; Kang *et al.* International Publication No. WO 92/18619; Dower *et al.* International Publication No. WO 91/17271; Winter *et al.* International Publication WO 92/20791; Markland *et al.* International Publication No. WO 92/15679; Breitling *et al.* International Publication WO 93/01288; McCafferty *et al.* International Publication No. WO 92/01047; Garrard *et al.* International Publication No. WO 92/09690; Ladner *et al.* International Publication No. WO 90/02809; Fuchs *et al.* (1991) *Bio/Technology* 9:1370-1372; Hay *et al.* (1992) *Hum Antibod Hybridomas* 3:81-85; Huse *et al.* (1989) *Science* 246:1275-1281; Griffiths *et al.* (1993) *EMBO J* 12:725-734; Hawkins *et al.* (1992) *J Mol Biol* 226:889-896; Clarkson *et al.* (1991) *Nature* 352:624-628; Gram *et al.* (1992) *PNAS* 89:3576-3580; Garrard *et al.* (1991) *Bio/Technology* 9:1373-1377; Hoogenboom *et al.* (1991) *Nuc Acid Res* 19:4133-4137; Barbas *et al.* (1991) *PNAS* 88:7978-7982; and McCafferty *et al.* *Nature* (1990) 348:552-554.

Additionally, recombinant anti-NIP45 antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in Robinson *et al.*

International Patent Publication PCT/US86/02269; Akira, *et al.* European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison *et al.* European Patent Application 173,494; Neuberger *et al.* PCT Application WO 86/01533; Cabilly *et al.* U.S. Patent No. 4,816,567; Cabilly *et al.* European Patent Application 125,023; Better *et al.* (1988) *Science* **240**:1041-1043; Liu *et al.* (1987) *PNAS* **84**:3439-3443; Liu *et al.* (1987) *J. Immunol.* **139**:3521-3526; Sun *et al.* (1987) *PNAS* **84**:214-218; Nishimura *et al.* (1987) *Canc. Res.* **47**:999-1005; Wood *et al.* (1985) *Nature* **314**:446-449; and Shaw *et al.* (1988) *J. Natl Cancer Inst.* **80**:1553-1559; Morrison, S. L. (1985) *Science* **229**:1202-1207; Oi *et al.* (1986) *BioTechniques* **4**:214; Winter U.S. Patent 5,225,539; Jones *et al.* (1986) *Nature* **321**:552-525; Verhoeyan *et al.* (1988) *Science* **239**:1534; and Beidler *et al.* (1988) *J. Immunol.* **141**:4053-4060.

An anti-NIP45 antibody (*e.g.*, monoclonal antibody) can be used to isolate NIP45 by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-NIP45 antibody can facilitate the purification of natural NIP45 from cells and of recombinantly produced NIP45 expressed in host cells. Moreover, an anti-NIP45 antibody can be used to detect NIP45 protein (*e.g.*, in a cellular lysate or cell supernatant). Detection may be facilitated by coupling (*i.e.*, physically linking) the antibody to a detectable substance. Accordingly, in one embodiment, an anti-NIP45 antibody of the invention is labeled with a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

IV. Pharmaceutical Compositions

The NIP45 proteins and anti-NIP45 antibodies of the invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the protein or antibody and a pharmaceutically acceptable carrier. As used herein the term "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. For example, solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.

The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a NIP45 protein or anti-NIP45 antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

V. Methods of the Invention

Another aspect of the invention pertains to a method of using the various NIP45 compositions of the invention. For example, the invention provides a method for detecting the presence of NIP45 protein or mRNA in a biological sample. The method involves contacting the biological sample with an agent capable of detecting NIP45 protein or mRNA such that the presence of NIP45 protein or mRNA is detected in the biological sample. A preferred agent for detecting NIP45 mRNA is a labeled nucleic acid probe capable of hybridizing to NIP45 mRNA. The nucleic acid probe can be, for example, the NIP45 cDNA of SEQ ID NO: 1, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900 or 1000 nucleotides in length and sufficient to specifically hybridize under stringent conditions to NIP45 mRNA. A preferred agent for detecting NIP45 protein is a labeled antibody capable of binding to NIP45 protein. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')₂) can be used. The term "labeled", with

regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (*i.e.*, physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids. For example, techniques for detection of NIP45 mRNA include Northern hybridizations and *in situ* hybridizations. Techniques for detection of NIP45 protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence.

The invention further provides methods for identifying agents that modulate an interaction between NIP45 and an NF-AT family protein. In one embodiment, the method comprises:

- 15 a) combining:
 - (i) NIP45, or an NF-AT-interacting portion thereof; and
 - (ii) an NF-AT family protein, or a NIP45-interacting portion thereof;in the presence and absence of a test compound;
- 20 b) determining the degree of interaction between (i) and (ii) in the presence and absence of the test compound; and
- c) identifying an agent that modulates an interaction between NIP45 and an NF-AT family protein.

Isolated NIP45 and/or NF-AT family proteins may be used in the method, or, alternatively, only portions of NIP45 and/or an NF-AT family protein may be used. For example, an isolated NF-AT Rel Homology Domain (or a larger subregion of NF-AT that includes the RHD) can be used as the NIP45-interacting portion of NF-AT. Likewise, a portion of NIP45 capable of binding to the NF-AT RHD may be used. In a preferred embodiment, one or both of (i) and (ii) are fusion proteins, such as GST fusion proteins (*e.g.*, GST-NF-AT RHD can be used as the NIP45-interacting portion of NF-AT). The degree of interaction between (i) and (ii) can be determined, for example, by labeling one of the proteins with a detectable substance (*e.g.*, a radiolabel), isolating the non-labeled protein and quantitating the amount of detectable substance that has become associated with the non-labeled protein. The assay can be used to identify agents that either stimulate or inhibit the interaction between NIP45 and an NF-AT family protein. An agent that stimulates the interaction between NIP45 and an NF-AT family protein is identified based upon its ability to increase the degree of interaction between (i) and (ii) as compared to the degree of interaction in the absence of the agent, whereas an agent that inhibits the interaction between NIP45 and an NF-AT family protein is identified based upon its ability to decrease the degree of interaction between (i) and (ii) as compared to the degree of

interaction in the absence of the agent. Assays systems for identifying agents that modulate SH2 domain-ligand interactions as described in U.S. Patent No. 5,352,660 by Pawson can be adapted to identifying agents that modulate the NIP45/NF-AT RHD interaction.

- In another embodiment, the invention provides a method for identifying a
- 5 compound that modulates the expression or activity of NIP45. The method comprises:
- a) preparing an indicator cell, wherein said indicator cell contains:
 - i) a recombinant expression vector encoding NIP45; and
 - ii) a vector comprising regulatory sequences of a Th2-associated cytokine gene operatively linked a reporter gene;
 - 10 b) contacting the indicator cell with a test compound;
 - c) determining the level of expression of the reporter gene in the indicator cell in the presence of the test compound;
 - d) comparing the level of expression of the reporter gene in the indicator cell in the presence of the test compound with the level of expression of the reporter gene in the
 - 15 indicator cell in the absence of the test compound; and
 - e) identifying a compound that modulates the expression or activity of NIP45.

- Recombinant expression vectors that can be used for expression of NIP45 in an indicator cell are known in the art (see discussions above and also the Examples). In one embodiment, within the expression vector the NIP45 coding sequences are operatively
- 20 linked to regulatory sequences that allow for constitutive expression of NIP45 in the indicator cell (e.g., viral regulatory sequences, such as a cytomegalovirus promoter/enhancer, can be used). Use of a recombinant expression vector that allows for constitutive expression of NIP45 in the indicator cell is preferred for identification of compounds that enhance or inhibit the activity of NIP45. In an alternative embodiment,
- 25 within the expression vector the NIP45 coding sequences are operatively linked to regulatory sequences of the NIP45 gene (i.e., the promoter regulatory region derived from the endogenous NIP45 gene). Use of a recombinant expression vector in which NIP45 protein expression is controlled by the native regulatory sequences of the NIP45 gene is preferred for identification of compounds that enhance or inhibit the transcriptional
- 30 expression of NIP45.

- Preferably, the Th2-associated cytokine is interleukin-4. It has previously shown that Th2-specific, inducible IL-4 expression can be directed by as little as 157 bp of the proximal IL-4 promoter in Th2 cells (Hodge, M. *et al.* (1995) *J. Immunol.* 154:6397-6405). Accordingly, in one embodiment, the method utilizes a reporter gene construct containing
- 35 this region of the proximal IL-4 promoter, most preferably nucleotides -157 to +58 (relative to the start site of transcription at +1) of the IL-4 promoter. Alternatively, stronger reporter gene expression can be achieved using a longer portion of the IL-4 upstream regulatory region, such as about 3 kb of upstream regulatory sequences. Suitable reporter gene constructs are described in Todd, M. *et al.* (1993) *J. Exp. Med.* 177:1663-1674.

A variety of reporter genes are known in the art and are suitable for use in the screening assays of the invention. Examples of suitable reporter genes include those which encode chloramphenicol acetyltransferase, beta-galactosidase, alkaline phosphatase or luciferase. Standard methods for measuring the activity of these gene products are known in the art.

A variety of cell types are suitable for use as an indicator cell in the screening assay. Preferably a cell line is used which does not normally express NIP45, such as a B cell (*e.g.*, the M12 B lymphoma cell line) or nonlymphoid cell lines, such as the HepG2 hepatoma cell line.

In one embodiment, the level of expression of the reporter gene in the indicator cell in the presence of the test compound is higher than the level of expression of the reporter gene in the indicator cell in the absence of the test compound and the test compound is identified as a compound that stimulates the expression or activity of the transcription factor. In another embodiment, the level of expression of the reporter gene in the indicator cell in the presence of the test compound is lower than the level of expression of the reporter gene in the indicator cell in the absence of the test compound and the test compound is identified as a compound that inhibits the expression or activity of the transcription factor.

In yet another embodiment, the invention provides a method identifying a protein that interacts with NIP45 comprising:

- a) providing a two hybrid assay including a host cell that contains:
 - i) a reporter gene operably linked to a transcriptional regulatory sequence;
 - ii) a first chimeric gene that encodes a first fusion protein, said first fusion protein including NIP45;
 - iii) a library of second chimeric genes that encodes second fusion proteins;

wherein expression of the reporter gene is sensitive to interactions between the first fusion protein, the second fusion protein and the transcriptional regulatory sequence;

- b) determining the level of expression of the reporter gene in the host cell;
- and
- c) identifying a protein that interacts with NIP45.

The method of the invention for identifying proteins that interact with NIP45 can be designed based on the two-hybrid assay system (also referred to as an interaction trap assay) known in the art (see *e.g.*, Field U.S. Patent No. 5,283,173; Zervos *et al.* (1993) *Cell* 72:223-232; Madura *et al.* (1993) *J. Biol. Chem.* 268:12046-12054; Bartel *et al.* (1993) *Biotechniques* 14:920-924; and Iwabuchi *et al.* (1993) *Oncogene* 8:1693-1696). The two-hybrid assay is generally used for identifying proteins that interact with a particular target protein. The assay employs gene fusions to identify proteins capable of interacting to

reconstitute a functional transcriptional activator. The transcriptional activator consists of a DNA-binding domain and a transcriptional activation domain, wherein both domains are required to activate transcription of genes downstream from a target sequence (such as an upstream activator sequence (UAS) for GAL4). DNA sequences encoding a target "bait" protein are fused to either of these domains and a library of DNA sequences is fused to the other domain. "Fish" fusion proteins (generated from the fusion library) capable of binding to the target-fusion protein (e.g., a target GAL4-fusion "bait") will generally bring the two domains (DNA-binding domain and transcriptional activation domain) into close enough proximity to activate the transcription of a reporter gene inserted downstream from the target sequence. Thus, the "fish" proteins can be identified by their ability to reconstitute a functional transcriptional activator (e.g., a functional GAL4 transactivator).

This general two-hybrid system can be applied to the identification of proteins that interact with NIP45 by construction of a target NIP45 fusion protein (e.g., a NIP45/GAL4 binding domain fusion as the "bait") and a cDNA library of "fish" fusion proteins (e.g., a cDNA/GAL4 activation domain library). The cDNA library can be prepared from a cell type of interest to identify proteins in that cell type that interact with NIP45. For example, the cDNA library can be prepared from T cells to identify proteins in T cells that interact with NIP45. The expression vector encoding the NIP45 fusion protein and the cDNA library are then introduced into a host cell that also contains a reporter gene construct linked to a regulatory sequence responsive to NIP45 (e.g., a region of the IL-4 promoter or a promoter containing NF-AT sites). cDNAs encoding proteins that interact with NIP45 can be identified based upon transactivation of the reporter gene construct. For further description of the two hybrid assay system, see Example 1.

Yet another aspect of the invention pertains to methods of modulating NIP45 activity in a cell. The modulatory methods of the invention involve contacting the cell with an agent that modulates NIP45 activity such that NIP45 activity in the cell is modulated. The agent may act by modulating the activity of NIP45 protein in the cell or by modulating transcription of the NIP45 gene or translation of the NIP45 mRNA. As used herein, the term "modulating" is intended to include inhibiting or decreasing NIP45 activity and stimulating or increasing NIP45 activity. Accordingly, in one embodiment, the agent inhibits NIP45 activity. An inhibitory agent may function, for example, by directly inhibiting NIP45 activity or by inhibiting an interaction between NF-AT and NIP45. In another embodiment, the agent stimulates NIP45 activity. A stimulatory agent may function, for example, by directly stimulating NIP45 activity or by promoting an interaction between NF-AT and NIP45. Methods for modulating NIP45 activity are described further in U.S. Serial No. _____, entitled "*Methods for Regulating T cell Subsets by Modulating Transcription Factor Activity*", filed on November 25, 1996 (Attorney Docket No. HUI-021CP), the entire contents of which are expressly incorporated herein by reference.

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are hereby incorporated by reference. Nucleotide and amino acid sequences deposited in public databases as referred to herein are also hereby incorporated by reference.

EXAMPLE 1: Isolation of a NIP45 cDNA Using a Yeast Two-Hybrid Interaction Trap Assay

A yeast two-hybrid interaction trap assay was used to isolate proteins that could directly bind to the RHD of NF-ATp. An NF-ATp(RHD)-Gal4 fusion protein was prepared for use as the "bait" in the yeast two-hybrid assay by cloning a 900 bp fragment of murine NF-ATp (McCaffrey, P.G. *et al.* (1993) *Science* 262:750-754), spanning amino acids 228 to 520, into the BamHI site of vector pEG202 (Gyuris, J. *et al.* (1993) *Cell* 75:791-803). In frame fusion of the NF-AT(p) polypeptide sequences to the Gal4 sequences was confirmed by DNA sequence analysis. This bait was used to screen a cDNA library prepared from the murine T cell line D10, constructed in the plasmid pJG4-5, to select for clones encoding polypeptides that interacted with the bait, using methodologies known in the art (see Gyuris, J. *et al.* (1993) *Cell* 75:791-803).

One class of interactors encoding a fusion protein with apparently high affinity for the NF-ATp(RHD)-Gal4 bait, as exhibited by high level of β -galactosidase activity and ability to confer leucine prototrophy, was isolated and termed NIP45 (NF-AT Interacting Protein 45). Figure 1 shows a photograph of yeast colonies (three representatives for each plasmid combination), cotransformed with the NIP45 plasmid and either the NF-ATp-RHD bait or control baits (Max-Gal4, CDK2-Gal4 and the control vector pEG202, expressing only an epitope tagged Gal4 protein), together with the LacZ reporter plasmid pSH18. The yeast colonies had been selected on appropriate media and were spotted onto plates containing Xgal and the nonrepressing carbon source galactose. Yeast colonies cotransformed with the NIP45 plasmid and the NF-ATp-RHD bait were blue in color, demonstrating expression of the LacZ reporter plasmid (indicative of NIP-45/NF-ATp-RHD interaction), whereas yeast colonies transformed with the NIP45 plasmid and the control baits were white in color, indicating no interaction of NIP45 with the control baits. Transformants were also tested on galactose containing media lacking leucine, and only those containing the NIP45 plasmid and the NF-ATp-RHD bait grew, further indicating the specific interaction of NIP45 with NF-ATp-RHD. The NIP45 cDNA isolated by the two-hybrid assay was a 1.9 kb DNA fragment.

EXAMPLE 2: Interaction of NIP45 and NF-ATp *In Vivo* in Mammalian Cells

The ability of the NIP45 polypeptide to interact specifically with NF-ATp *in vivo* was tested in mammalian cells. The 1.9 kb NIP45 cDNA insert selected in the yeast two-hybrid system (described in Example 1) was subcloned into a mammalian expression vector which fuses the coding region to an epitope tag from a influenza hemagglutinin (HA) peptide, vector pCEP4-HA (Herrscher, R.F. *et al.* (1995) *Genes Dev.* 9:3067-3082), to create the expression vector NIP45-HA. This tagged construct was then cotransfected with an NF-ATp expression plasmid into HepG2 cells (which express low levels of NF-ATp). As controls, HepG2 cells also were cotransfected with NIP45-HA along with the parental expression vector for the NF-ATp construct (*i.e.*, the expression vector without the NF-ATp insert) or with the NF-ATp expression vector along with an out of frame fusion of NIP45 with the epitope tag. Lysates were prepared from the transfected cells and immunoprecipitated with anti-NF-ATp antibody. Western blot analysis was then performed on the immunoprecipitated material using either anti-NF-ATp or anti-HA antibodies.

The results of this experiment are shown in Figure 2. Western blot analysis of these samples using an HA-specific monoclonal antibody (mAb) demonstrated that the anti-NF-ATp antibody used for immunoprecipitation coimmunoprecipitated the HA-tagged NIP45 polypeptide. The lane showing transfection with only NIP45-HA (middle lane) reveals the low endogenous level of NF-ATp present in these cells. The amount of HA-tagged NIP45 protein immunoprecipitated was further increased by cotransfection with the NF-ATp expression plasmid demonstrating the specificity of this interaction (right lane). Western blot analysis of untreated lysates demonstrated that equivalent levels of NIP45-HA polypeptide were expressed in the samples tested for coimmunoprecipitation of NIP45-HA anti-NF-ATp antibodies. Furthermore, no immunoreactive material for either NF-ATp or the HA tagged protein was detected when performing immunoprecipitation using normal rabbit serum. These experiments demonstrate that NF-AT and NIP45 physically associate *in vivo* in mammalian cells.

EXAMPLE 3: Structural Analysis of NIP45 cDNAs

The 1.9 kb NIP45 cDNA insert from the clone isolated using the two-hybrid assay (described in Example 1) was used to screen a D10.G4 T cell lambda zap II cDNA library (Stratagene) to identify full length clones. Screening of a library containing approximately 8×10^5 clones yielded 7 hybridizing clones most of which did not extend as far towards the 5' end as the original isolate. Sequence analysis of the longest clone (2.8 kb), however, demonstrated identity to the original clone at the 5' end. The structures of the original 1.9 kb cDNA isolate and the longest 2.8 kb cDNA isolate are compared in Figure 3. The 2.8

kb cDNA isolate contained an additional segment of 180 bp located 868 bp downstream from the 5' end of the original clone. Junction sequences at the ends of this 180 nucleotide segment indicate it to be an unspliced intron and conceptual translation of the nucleotide sequence within this region revealed an in-frame stop codon. Much of the additional sequence in this clone was at the 3' end and represented an extensive 3' untranslated region followed by a poly-A+ tail (see Figure 3). Such extensive 3' untranslated regions have been observed in many genes. Allowing for the splicing of the small intron and translation of the single large open reading frame, the 2.8 kb cDNA clone is predicted to encode an identical polypeptide to that of the original 1.9 kb isolate.

The nucleotide and predicted amino acid sequences of the 1.9 kb cDNA isolate are shown in Figure 4 (and in SEQ ID NOs: 1 and 2, respectively). The coding region is shown from the first initiation codon through the first in frame stop codon. The nucleotide and amino acid positions are indicated to the right of the primary sequence. Conceptual translation of the 1.9 kb nucleotide sequence predicted a polypeptide of 412 amino acids with a molecular mass of 45 Kd, and hence the protein has been termed NF-AT Interacting Protein 45 (NIP45). Inspection of the amino acid sequence of NIP45 revealed a highly basic domain at the N-terminus, in which 13 of 32 amino acid are basic. This region is underlined in Figure 4. This basic region appears as a hydrophilic stretch in the hydrophobicity plot shown in Figure 5.

EXAMPLE 4: Tissue Expression of NIP45 mRNA

Northern blot analysis of RNA from different murine tissues was performed to investigate the tissue expression of NIP45 mRNA. 10 µg of total RNA from various tissues was separated on denaturing agarose gels, blotted and hybridized with a radiolabelled 1.4 kb NIP45 cDNA fragment. Samples were controlled for equivalent loading of RNA by comparison of ethidium bromide fluorescence. The results of the Northern blot analysis are shown in Figure 6. The hybridizations revealed a transcript of approximately 3.1 kb, which is of comparable size to the longest cDNA clones. RNA from testis contained an additional 1.4 Kb hybridizing species. The highest levels of NIP45 transcripts were seen in spleen, thymus and testis. The preferential expression in lymphoid organs may indicate a specific function for NIP45 in the immune system. The low intensity hybridization signal and the rare occurrence of NIP45 cDNA clones in the T cell cDNA library indicate that the NIP45 RNA is a relatively rare message.

EXAMPLE 5: Subcellular Localization of NIP45

Subcellular localization of epitope tagged NIP45 protein was determined by indirect immunofluorescence. BHK cells were transfected with 1 µg of an expression construct

encoding an HA-epitope tagged NIP45 (pCEP4-HA), using methodologies known in the art (see Heald, R. *et al.* (1993) *Cell* 74:463-474). Transfected cells were incubated overnight, fixed, permeabilized as described (Heald, R. *et al.* (1993) *supra*) and probed with an anti-HA mAb 12CA5 (Boehringer Mannheim) plus indocarbocyanine labelled donkey anti-mouse antibody (Jackson ImmunoResearch) and then counterstained with the dye Hoechst 33258. The results are shown in Figures 7A-B. Nuclear staining of NIP45 was observed with the indocarbocyanine labelled secondary reagent (see Figure 7A) by comparison to the same cells counterstained with the DNA staining dye Hoechst 33258 (see Figure 7B). The fluorescence pattern indicates that NIP45 is evenly distributed throughout the nucleus. Furthermore, this pattern matched that seen for cells transfected with NF-AT4 and stimulated with ionomycin (Shibasaki, F. *et al.* (1996) *Nature* 382:370-373; see also below). Stimulation with PMA and/or ionomycin did not affect the subcellular localization of this NIP45.

Control experiments were also performed on BHK cells transfected with NF-AT4. Cells were incubated overnight in culture media and either fixed directly or first stimulated with 1 mM ionomycin for 10 minutes before fixation and then processed as described above. The results are shown in Figures 7C-F. Unstimulated (Figs. 7C and 7D) or ionomycin treated (Figs. 7E and 7F) NF-AT4 transfectants were probed with an anti-NF-AT4 specific antibody followed by a indocarbocyanine labelled secondary reagent and Hoechst 33258. Indocarbocyanine fluorescence demonstrates the pattern of staining for cytoplasmic localized NF-AT4 in unstimulated transfectants (Fig. 7C) and nuclear localized NF-AT4 in stimulated cells (Fig. 7E). Adjacent panels (Fig. 7D and 7F, respectively) show the same field exposed for detection of nuclei by staining with Hoechst 33258.

The effect of NIP45 on the nuclear translocation of NF-AT4 also was investigated. HepG2 cells were transfected with either NF-AT4 or NF-AT4 plus NIP45 and stimulated the following day with 1 μ M ionomycin for 0, 2, 4, 8 or 15 minutes. For one sample, the cells were stimulated for 15 minutes with ionomycin and then washed with fresh media and allowed to rest for an additional 15 minutes (indicated as "15 min. + 15 min. rest" in Table 1). This analysis is designed to examine the function of NIP45 as a nuclear retention factor. Fifteen minutes has been shown to be sufficient time for NF-AT4 to be exported to the cytoplasm (Shibasaki, F. *et al.* (1996) *Nature* 382:370-373). All samples were then fixed and analyzed by immunofluorescence for translocation of NF-AT4 as described above. The results are summarized below in Table 1. Subcellular localization of NF-AT4 in the cytoplasm is indicated by a (-) and nuclear translocation of NF-AT4 is indicated by (+).

Table 1: Nuclear Translocation of NF-AT4

<u>Time</u>	<u>Ionomycin</u>	<u>Ionomycin + NIP45</u>
0 min.	-	-
2 min.	+/-	+/-
4 min.	+/-	+/-
8 min.	+	+
15 min.	+	+
15 min. + 15 min. rest	-	-

- No difference in the rate of nuclear import or export of NF-AT4 was observed in the presence of NIP45, indicating that nuclear trafficking of NF-AT4 in response to changes in intracellular calcium levels was not affected by the overexpression of exogenous NIP45.

EXAMPLE 6: Functional Activity of NIP45 in Regulating Gene Expression

- To test for a functional role of NIP45 in NF-AT-driven transcription, NIP45 was expressed at high levels in HepG2 cells. HepG2 cells were chosen because they have low levels of endogenous NF-AT, and ectopic expression of NF-AT family member proteins has been shown to transactivate NF-AT-driven transcription in this cell line in the absence of exogenous stimulation (Hoey, T. *et al.* (1995) *Immunity* 2:461-472). HepG2 cells were transfected with a 3X NF-AT-CAT reporter from the IL-2 gene (Venkataraman, L. *et al.* (1994) *Immunity* 1:189-196) and control or expression plasmids for a NIP45 and NF-AT family members (NF-ATp, NF-ATc, NF-AT3, NF-AT4). HepG2 cells were transfected by the DEAE-Dextran method as described in Hoey, T. *et al.* (1995) *supra*, and CAT assays were performed according to standard methodologies. The results are shown in Figure 8. One representative assay for each combination is shown adjacent to a bar graph representing relative CAT activity for each group. Fold induction was calculated by normalizing the CAT activity of cells transfected with the CAT reporter and each parental expression vector to one. Values represent the relative level of CAT expression above this control transfection. All transfections were performed at least three times with one representative autoradiograph shown.
- Transfection of NIP45 alone into HepG2 cells with a 3X NF-AT-CAT reporter did not lead to a significant increase in CAT expression demonstrating that NIP45 cannot act on its own to transactivate an NF-AT target sequence. Overexpression of NF-ATp alone resulted in substantial (6-fold over vector control) transactivation of the NF-AT-CAT reporter, consistent with previous reports (Hoey, T. *et al.* (1995) *supra*). Cotransfection of NIP45 plus NF-ATp resulted in a 4-5 fold increase in CAT activity relative to transfection with NF-ATp alone and a 25-30 fold increase over that seen with vector alone. This increase was not observed when a mutant 3X NF-AT-CAT reporter or a control MHC class

II promoter reporter was used thus demonstrating its target site specificity. To confirm that the polypeptide product encoded by the NIP45 cDNA was responsible for this enhanced transactivation, a frame shift mutation was introduced in the coding region by creating a two base deletion at nucleotide 50. This alteration results in the introduction of missense mutations at amino acid 13 and termination of the polypeptide after an additional 22 residues. Assays using this NIP45 Δ construct demonstrated its failure to transactivate the NF-AT reporter in the presence or absence of NF-ATp thus confirming that the enhanced transactivation observed was due to the polypeptide expressed from NIP45 cDNA. Transactivation experiments were also performed in the B cell line M12 and the T cell clone D10 with similar although less dramatic results, which may be due to higher levels of endogenous NIP45 or NF-ATp in these latter cell lines. These experiments demonstrate that NIP45 substantially and specifically potentiates transcription induced by NF-ATp, an activity that requires interaction with NF-ATp.

NF-AT proteins share approximately 70% identity within the RHD, raising the possibility that NIP45 could also interact with other NF-AT family members. To test this, NIP45 was cotransfected as above with expression constructs encoding either NF-ATc, NF-AT3 or NF-AT4 plus the 3X NF-AT-CAT reporter plasmid. The results of these experiments are also shown in Figure 8. It has previously been demonstrated that all NF-AT family members can transactivate a reporter gene containing 3 copies of an NF-AT/AP1 site when overexpressed in HepG2 cells, although to different levels (Hoey, T. *et al.* (1995) *supra*). In the absence of NIP45, NF-ATp was the most potent transactivator of the NF-AT-CAT reporter followed by NF-ATc and NF-AT3 with only weak transactivation by NF-AT4, consistent with previous data (McCaffrey, P.G. *et al.* (1993) *Science* 262:750-754). When NF-ATc, NF-AT3 or NF-AT4 were cotransfected with NIP45, NIP45 substantially potentiated both NF-ATc and NF-AT3-driven transactivation and weakly potentiated NF-AT4-mediated transactivation (Figure 8). Cooperation with NF-ATc in HepG2 cells is consistent with the observation that NIP45 interacts with an NF-ATc RHD bait in yeast cells. Overall, NIP45 overexpression resulted in a 4-fold increase in transactivation by NF-ATc, a 3-fold increase in NF-AT3-driven transactivation and a 2-fold increase in NF-AT4-driven transcription. The ability of NIP45 to potentiate the activity of all NF-AT family members is not surprising given the high degree of sequence conservation of the RHD of the NF-AT family members. A sequence comparison of the NF-AT RHD domains reveals a higher level of sequence identity in the amino terminal portion compared to that of the carboxyl terminus (Hoey, T. *et al.* (1995) *supra*). Thus it is likely that the NIP45/NF-AT interaction site is located in the 5' portion of the RHD.

Although a reporter construct containing multiple copies of the NF-AT binding site provides a sensitive method for measuring transactivation by NF-AT and NIP45, we sought to determine if NIP45 was functional in the context of a native NF-AT-dependent promoter. IL-4 expression is highly tissue specific and restricted to the Th2 subset of T

cells and to mast cells. The IL-4 promoter contains multiple NF-AT binding sites which have been shown to be critical for expression of IL-4 (Rooney, J.W. *et al.* (1995) *Immunity* 2:473-483). Furthermore, the proto-oncogene c-maf has been shown to direct tissue specific expression of IL-4 (U.S. Serial No. 08/636,602). Thus, the IL-4 promoter is not active in the HepG2 cell line but can be activated by the introduction of NF-ATp and c-maf. In cotransfection experiments carried out as described above, HepG2 cells were transfected with an IL-4-CAT reporter construct (extending to -732 bp of the IL-4 promoter) and expression vectors or controls for NIP45, NF-ATp and c-Maf. The controls for NIP45 was a frame shift mutant at amino acid 13. Controls for NF-ATp and c-Maf were the empty expression vectors pREP4 and pMEX respectively (Ho, I.C. *et al.* (1996) *Cell* 85:973-983). The results of these experiments are shown in Figure 9 (representative CAT assays and bar graphs are depicted as in Figure 8). The data indicate that introduction of NIP45 together with NF-ATp and c-Maf results in an additional 9-fold increase in the activity of the IL-4 promoter relative to that seen for NF-ATp and c-Maf alone. NIP45 also increased the activity of the IL-4 promoter in the absence of transfected NF-ATp, an effect likely due to interaction with endogenous NF-ATp.

EXAMPLE 7: Transient Overexpression of NIP45 with NF-ATp and c-Maf Results in Endogenous IL-4 Production

To determine whether the combination of NIP45, NF-ATp and c-Maf was sufficient to induce endogenous IL-4 expression by cells that do not normally produce IL-4, M12 B lymphoma cells were transiently cotransfected with expression plasmids for NF-ATp and c-Maf together with NIP45 or pCI vector control. M12 cells were transiently transfected by electroporation as previously described (Ho, I.C. *et al.* (1996) *Cell* 85:973-983) by incubating 3×10^6 cells in 0.4 ml of PBS with 5 μ g of each plasmid for 10 minutes at room temperature prior to electroporation at 975 μ F, 280 V. Levels of IL-4 in the supernatants harvested 72 hours later were measured by a commercially available IL-4 ELISA (Pharmingen), performed according to the manufacturer's instructions except with modification as described (Ho, I.C. *et al.* (1996) *supra*). Four independent sets of transient transfections were done and assayed for secretion of IL-4 into the culture supernatant. Results from a representative experiment from one of the four independent transfections is shown in Figure 10. For each set of transfections, inclusion of NIP45 led to a dramatic increase in IL-4 production. Cells transfected with NIP45 produced 50-200 fold more endogenous IL-4 than cells that did not receive NIP45, in which IL-4 production was near the limit of detection.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

5

0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

- 39 -
SEQUENCE LISTING

(1) GENERAL INFORMATION:

- 5 (i) APPLICANT: Glimcher, Laurie H.
Hodge, Martin R.
- 10 (ii) TITLE OF INVENTION: NF-AT-INTERACTING PROTEIN NIP45 AND METHODS
OF USE THEREFOR
- (iii) NUMBER OF SEQUENCES: 2
- 15 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: LAHIVE & COCKFIELD
(B) STREET: 60 State Street, suite 510
(C) CITY: Boston
(D) STATE: Massachusetts
(E) COUNTRY: USA
20 (F) ZIP: 02109-1875
- (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
25 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
30 (B) FILING DATE:
(C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER:
35 (B) FILING DATE:
- (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Giulio A. DeConti, Jr.
40 (B) REGISTRATION NUMBER: 31,503
(C) REFERENCE/DOCKET NUMBER: HUI-026
- (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (617)227-7400
45 (B) TELEFAX: (617)227-5941

(2) INFORMATION FOR SEQ ID NO:1:

- 50 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1946 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- 55 (ii) MOLECULE TYPE: cDNA
- (ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 13..1248

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

5	ACAGTGTGGG AG ATG GCG GAA CCA CTG AGG GGA CGT GGT CCG AGG TCC	48
	Met Ala Glu Pro Leu Arg Gly Arg Gly Pro Arg Ser	
	1 5 10	
10	CGC GGT GGC CGA GGC GCT CGG AGA GCC CGA GGC GCC CGT GGC CGG TGT	96
	Arg Gly Gly Arg Gly Ala Arg Arg Ala Arg Gly Ala Arg Gly Arg Cys	
	15 20 25	
15	CCT CGC GCC CGG CAG TCT CCG GCT AGG CTC ATT CCA GAC ACC GTG CTT	144
	Pro Arg Ala Arg Gln Ser Pro Ala Arg Leu Ile Pro Asp Thr Val Leu	
	30 35 40	
20	GTG GAC TTG GTC AGT GAC AGC GAC GAA GAG GTC TTG GAA GTC GCA GAC	192
	Val Asp Leu Val Ser Asp Ser Asp Glu Glu Val Leu Glu Val Ala Asp	
	45 50 55 60	
25	CCA GTA GAG GTG CCG GTC GCC GCG CTC CCC GCG CCG GCT AAA CCT GAG	240
	Pro Val Glu Val Pro Val Ala Arg Leu Pro Ala Pro Ala Lys Pro Glu	
	65 70 75	
30	CAG GAC AGC GAC AGT GAC AGT GAA GGG GCG GCC GAG GGG CCT GCG GGA	288
	Gln Asp Ser Asp Ser Asp Ser Glu Gly Ala Ala Glu Gly Pro Ala Gly	
	80 85 90	
35	GCC CCG CGT ACA TTG GTG CGA CGG CGG CGG CGG CGG CTG CTG GAT CCC	336
	Ala Pro Arg Thr Leu Val Pro Arg Arg Arg Arg Arg Leu Leu Asp Pro	
	95 100 105	
40	GGA GAG GCG CCG GTG GTC CCA GTG TAC TCC GGG AAG GTA CAG AGC AGC	384
	Gly Glu Ala Pro Val Val Pro Val Tyr Ser Gly Lys Val Gln Ser Ser	
	110 115 120	
45	CTC AAC CTC ATT CCA GAT AAT TCA TCC CTC TTG AAA CTG TGC CCT TCA	432
	Leu Asn Leu Ile Pro Asp Asn Ser Ser Leu Leu Lys Leu Cys Pro Ser	
	125 130 135 140	
50	GAG CCT GAA GAT GAG GCA GAT CTG ACA AAT TCT GGC AGT TCT CCC TCT	480
	Glu Pro Glu Asp Glu Ala Asp Leu Thr Asn Ser Gly Ser Ser Pro Ser	
	145 150 155	
55	GAG GAT GAT GCC CTG CCT TCA GGT TCT CCC TGG AGA AAG AAG CTC AGA	528
	Glu Asp Asp Ala Leu Pro Ser Gly Ser Pro Trp Arg Lys Lys Leu Arg	
	160 165 170	
60	AAG AAG TGT GAG AAA GAA GAA AAG AAA ATG GAA GAG TTT CCG GAC CAG	576
	Lys Lys Cys Glu Lys Glu Glu Lys Lys Met Glu Glu Phe Pro Asp Gln	
	175 180 185	
65	GAC ATC TCT CCT TTG CCC CAA CCT TCG TCA AGG AAC AAA AGC AGA AAG	624
	Asp Ile Ser Pro Leu Pro Gln Pro Ser Ser Arg Asn Lys Ser Arg Lys	
	190 195 200	
70	CAT ACG GAG GCG CTC CAG AAG CTA AGG GAA GTG AAC AAG CGT CTC CAA	672
	His Thr Glu Ala Leu Gln Lys Leu Arg Glu Val Asn Lys Arg Leu Gln	
	205 210 215 220	

	GAT CTC CGC TCC TGC CTG AGC CCC AAG CAG CAC CAG AGT CCA GCC CTT	720
	Asp Leu Arg Ser Cys Leu Ser Pro Lys Gln His Gln Ser Pro Ala Leu	
5	225 230 235	
	CAG AGC ACA GAT GAT GAG GTG GTC CTA GTG GAA GGG CCT GTC TTG CCA	768
	Gln Ser Thr Asp Asp Glu Val Val Leu Val Glu Gly Pro Val Leu Pro	
	240 245 250	
10	CAG AGC TCT CGA CTC TTT ACA CTC AAG ATC CGG TGC CGG GCT GAC CTA	816
	Gln Ser Ser Arg Leu Phe Thr Leu Lys Ile Arg Cys Arg Ala Asp Leu	
	255 260 265	
15	GTG AGA CTG CCT GTC AGG ATG TCG GAG CCC CTT CAG AAT GTG GTG GAT	864
	Val Arg Leu Pro Val Arg Met Ser Glu Pro Leu Gln Asn Val Val Asp	
	270 275 280	
20	CAC ATG GCC AAT CAT CTT GGG GTG TCT CCA AAC AGG AIT CTT TTG CTT	912
	His Met Ala Asn His Leu Gly Val Ser Pro Asn Arg Ile Leu Leu Leu	
	285 290 295 300	
	TTT GGA GAG AGT GAA CTG TCT CCT ACT GCC ACC CCT AGT ACC CTA AAG	960
	Phe Gly Glu Ser Glu Leu Ser Pro Thr Ala Thr Pro Ser Thr Leu Lys	
	305 310 315	
25	CTT GGA GTG GCT GAC ATC ATT GAT TGT GTG GTG CTA GCA AGC TCT TCA	1008
	Leu Gly Val Ala Asp Ile Ile Asp Cys Val Val Leu Ala Ser Ser Ser	
	320 325 330	
30	GAG GCC ACA GAG ACA TCC CAG GAG CTC CGG CTC CGG GTG CAG GGG AAG	1056
	Glu Ala Thr Glu Thr Ser Gln Glu Leu Arg Leu Arg Val Gln Gly Lys	
	335 340 345	
35	GAG AAA CAC CAG ATG TTG GAG ATC TCA CTG TCT CCT GAT TCT CCT CTT	1104
	Glu Lys His Gln Met Leu Glu Ile Ser Leu Ser Pro Asp Ser Pro Leu	
	350 355 360	
40	AAG GTT CTC ATG TCA CAC TAT GAG GAA GCC ATG GGA CTC TCT GGA CAC	1152
	Lys Val Leu Met Ser His Tyr Glu Glu Ala Met Gly Leu Ser Gly His	
	365 370 375 380	
	AAG CTC TCC TTC TTC TTT GAT GGG ACA AAG CTT TCA GGC AAG GAG CTG	1200
	Lys Leu Ser Phe Phe Phe Asp Gly Thr Lys Leu Ser Gly Lys Glu Leu	
	385 390 395	
45	CCA GCT GAT CTG GGC CTG GAA TCC GGA GAT CTC ATC GAA GTC TGG GGC	1248
	Pro Ala Asp Leu Gly Leu Glu Ser Gly Asp Leu Ile Glu Val Trp Gly	
	400 405 410	
50	TGAAGCTCTC ACCCTGTTCG GACGCAAAGC CAAGACATGG AGACAATAGC TCCCAATTTT	1308
	ATTATTGTGA TTTTTCGCCC CATAGGGCT AACAGAACT GAATTAGAAC TTGTTTACTT	1368
	ATTATTCTT GGTGCTGGGG ATTGAACCCC AGACTATGCA CATGCTAAGG ATGTATGAAG	1428
55	TGGAGGCAAA ACCAAGGCAT TACCTTTAGC CAGCCTCTAG TAGACTGTAG TGTCAAGCAA	1488
	GTGGCTACTT GGTAGTTGTG TGGCTCTGTG TATGTTTGTG CTGTATTGG CAGCCCTGG	1548

09102611.11693

GGCACATAGA AGGACACCTTG GCTTCCCTAC CATTTCACGT TCGCTGGTGC CCTTTCCTTC 1608
 ATCAGATGAC TTCTGTGAAG CTGCCTATGT TGAGTGTGTT GAACTAAATG AGCTCTGCTT 1668
 5 TGGGTGTCCA GGCCTGGGGT TGTGCGCGCA GTTGGAGCCA GCAGTGACTT CACTCTGACT 1728
 TGGGACTGAG AATGCATTTC CTGGTGGAGA CACTCGGGTG CAGAAATATA ACAGAAGGTG 1788
 10 ACATACATGC TGAAGCTGAG GACTAGTTCG AAAGTTAACG ACGTTGCATT TTCAGCCTTG 1848
 GGTATCTCTT CTGCCTGCCA GGACTCTAGC CAGTGTCTGG TACACACTTC TTGGCATGGA 1908
 CACCTAGGTC GACGCGGGCG CGATTCGGCC GACTCGAG 1946

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 412 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Ala Glu Pro Leu Arg Gly Arg Gly Pro Arg Ser Arg Gly Gly Arg
 1 5 10 15
 30 Gly Ala Arg Arg Ala Arg Gly Ala Arg Gly Arg Cys Pro Arg Ala Arg
 20 25 30
 Gln Ser Pro Ala Arg Leu Ile Pro Asp Thr Val Leu Val Asp Leu Val
 35 40 45
 35 Ser Asp Ser Asp Glu Glu Val Leu Glu Val Ala Asp Pro Val Glu Val
 50 55 60
 40 Pro Val Ala Arg Leu Pro Ala Pro Ala Lys Pro Glu Gln Asp Ser Asp
 65 70 75 80
 Ser Asp Ser Glu Gly Ala Ala Glu Gly Pro Ala Gly Ala Pro Arg Thr
 85 90 95
 45 Leu Val Arg Arg Arg Arg Arg Arg Leu Leu Asp Pro Gly Glu Ala Pro
 100 105 110
 Val Val Pro Val Tyr Ser Gly Lys Val Gln Ser Ser Leu Asn Leu Ile
 115 120 125
 50 Pro Asp Asn Ser Ser Leu Leu Lys Leu Cys Pro Ser Glu Pro Glu Asp
 130 135 140
 55 Glu Ala Asp Leu Thr Asn Ser Gly Ser Ser Pro Ser Glu Asp Asp Ala
 145 150 155 160
 Leu Pro Ser Gly Ser Pro Trp Arg Lys Lys Leu Arg Lys Lys Cys Glu
 165 170 175

010261 111693

Lys Glu Glu Lys Lys Met Glu Glu Phe Pro Asp Gln Asp Ile Ser Pro
 180 185 190
 5 Leu Pro Gln Pro Ser Ser Arg Asn Lys Ser Arg Lys His Thr Glu Ala
 195 200 205
 Leu Gln Lys Leu Arg Glu Val Asn Lys Arg Leu Gln Asp Leu Arg Ser
 210 215 220
 10 Cys Leu Ser Pro Lys Gln His Gln Ser Pro Ala Leu Gln Ser Thr Asp
 225 230 235 240
 Asp Glu Val Val Leu Val Glu Gly Pro Val Leu Pro Gln Ser Ser Arg
 245 250 255
 15 Leu Phe Thr Leu Lys Ile Arg Cys Arg Ala Asp Leu Val Arg Leu Pro
 260 265 270
 20 Val Arg Met Ser Glu Pro Leu Gln Asn Val Val Asp His Met Ala Asn
 275 280 285
 His Leu Gly Val Ser Pro Asn Arg Ile Leu Leu Leu Phe Gly Glu Ser
 290 295 300
 25 Glu Leu Ser Pro Thr Ala Thr Pro Ser Thr Leu Lys Leu Gly Val Ala
 305 310 315 320
 Asp Ile Ile Asp Cys Val Val Leu Ala Ser Ser Ser Glu Ala Thr Glu
 325 330 335
 30 Thr Ser Gln Glu Leu Arg Leu Arg Val Gln Gly Lys Glu Lys His Gln
 340 345 350
 35 Met Leu Glu Ile Ser Leu Ser Pro Asp Ser Pro Leu Lys Val Leu Met
 355 360 365
 Ser His Tyr Glu Glu Ala Met Gly Leu Ser Gly His Lys Leu Ser Phe
 370 375 380
 40 Phe Phe Asp Gly Thr Lys Leu Ser Gly Lys Glu Leu Pro Ala Asp Leu
 385 390 395 400
 Gly Leu Glu Ser Gly Asp Leu Ile Glu Val Trp Gly
 405 410

01 FEB 11 11:03

CLAIMS

We claim:

- 5 1. An isolated nucleic acid molecule comprising a nucleotide sequence encoding NIP45 or a biologically active portion thereof.
2. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least 60 %
10 homologous to the amino acid sequence of SEQ ID NO: 2 and interacts with the Rel Homology Domain of an NF-AT family protein.
3. The isolated nucleic acid molecule of claim 2, wherein the protein comprises an amino acid sequence at least 70 % homologous to the amino acid sequence of SEQ ID
15 NO: 2.
4. The isolated nucleic acid molecule of claim 2, wherein the protein comprises an amino acid sequence at least 80 % homologous to the amino acid sequence of SEQ ID
20 NO: 2.
5. The isolated nucleic acid molecule of claim 2, wherein the protein comprises an amino acid sequence at least 90 % homologous to the amino acid sequence of SEQ ID
25 NO: 2.
6. An isolated nucleic acid molecule at least 15 nucleotides in length which hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1.
7. The isolated nucleic acid molecule of claim 6 which comprises a naturally-
30 occurring nucleotide sequence.
8. The isolated nucleic acid molecule of claim 6 which encodes mouse NIP45.
9. The isolated nucleic acid molecule of claim 6 which encodes human NIP45.
35
10. An isolated nucleic acid molecule comprising the coding region of the nucleotide sequence of SEQ ID NO: 1.

11. The isolated nucleic acid molecule of claim 10, comprising the nucleotide sequence of SEQ ID NO: 1.
12. An isolated nucleic acid molecule encoding the amino acid sequence of SEQ ID NO: 2.
13. An isolated nucleic acid molecule encoding a NIP45 fusion protein.
14. An isolated nucleic acid molecule which is antisense to the nucleic acid molecule of claim 1.
15. An isolated nucleic acid molecule which is antisense to the coding strand of a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1.
16. The isolated nucleic acid molecule of claim 15 which is antisense to a coding region of the coding strand of the nucleotide sequence of SEQ ID NO: 1.
17. The isolated nucleic acid molecule of claim 15 which is antisense to a noncoding region of the coding strand of the nucleotide sequence of SEQ ID NO: 1.
18. A vector comprising the nucleic acid molecule of claim 1.
19. The vector of claim 18, which is a recombinant expression vector.
20. The vector of claim 19, which encodes a protein comprising the amino acid sequence of SEQ ID NO: 2.
21. The vector of claim 19, which comprises the coding region of the nucleotide sequence of SEQ ID NO: 1.
22. A host cell containing the vector of claim 18.
23. A host cell containing the recombinant expression vector of claim 19.
24. A method for producing NIP45 protein comprising culturing the host cell of claim 23 in a suitable medium until NIP45 protein is produced.
25. The method of claim 24, further comprising isolating NIP45 protein from the medium or the host cell.

26. An isolated NIP45 protein or a biologically active portion thereof.
27. An isolated protein which comprises an amino acid sequence at least 60 %
5 homologous to the amino acid sequence of SEQ ID NO: 2 and interacts with the Rel
Homology Domain of an NF-AT family protein.
28. The isolated protein of claim 27, which is at least 70% homologous to the
amino acid sequence of SEQ ID NO: 2.
- 10 29. The isolated protein of claim 27, which is at least 80% homologous to the
amino acid sequence of SEQ ID NO: 2.
30. The isolated protein of claim 27, which is at least 90% homologous to the
15 amino acid sequence of SEQ ID NO: 2.
31. A fusion protein comprising a NIP45 polypeptide operatively linked to a
non-NIP45 polypeptide.
- 20 32. An antigenic peptide of NIP45 comprising at least 8 amino acid residues of
the amino acid sequence shown in SEQ ID NO: 2, the peptide comprising an epitope of
NIP45 such that an antibody raised against the peptide forms a specific immune complex
with NIP45.
- 25 33. An antibody that specifically binds NIP45 protein.
34. The antibody of claim 33, which is a monoclonal antibody.
35. The antibody of claim 34, which is coupled to a detectable substance.
- 30 36. A pharmaceutical composition comprising the antibody of claim 34 and a
pharmaceutically acceptable carrier.
37. A nonhuman transgenic animal that contains cells carrying a transgene
35 encoding NIP45 protein.
38. The nonhuman transgenic animal of claim 37, which contains cells having
an altered endogenous NIP45 gene.

39. A method for identifying a compound that modulates an interaction between NIP45 and an NF-AT family protein, comprising:

a) combining:

(i) NIP45, or an NF-AT-interacting portion thereof; and

(ii) an NF-AT family protein, or a NIP45-interacting portion thereof;

in the presence and absence of a test compound;

b) determining the degree of interaction between (i) and (ii) in the presence and absence of the test compound; and

c) identifying an agent that modulates an interaction between NIP45 and an NF-AT family protein.

40. The method of claim 39, wherein the NIP45-interacting portion of the NF-AT family protein comprises the Rel Homology Domain of the NF-AT family protein.

41. The method of claim 39, wherein the degree of interaction between (i) and (ii) is determined by labeling (i) or (ii) with a detectable substance, isolating non-labeled (i) or (ii) and quantitating the amount of labeled (i) or (ii) that has become associated with non-labeled (i) or (ii).

42. The method of claim 39, wherein the test compound increases the degree of interaction between (i) and (ii), as compared to the degree of interaction in the absence of the test compound, and the test compound is identified as an agent that stimulates an interaction between NIP45 and an NF-AT family protein.

43. The method of claim 39, wherein the test compound decreases the degree of interaction between (i) and (ii), as compared to the degree of interaction in the absence of the test compound, and the test compound is identified as an agent that inhibits an interaction between NIP45 and an NF-AT family protein.

44. A method for identifying a compound that modulates the expression or activity of NIP45 comprising:

a) preparing an indicator cell, wherein said indicator cell contains:

i) a recombinant expression vector encoding NIP45; and

ii) a vector comprising regulatory sequences of a Th2-associated cytokine

gene operatively linked a reporter gene;

b) contacting the indicator cell with a test compound;

c) determining the level of expression of the reporter gene in the indicator cell in the presence of the test compound;

d) comparing the level of expression of the reporter gene in the indicator cell in the presence of the test compound with the level of expression of the reporter gene in the indicator cell in the absence of the test compound; and

e) identifying a compound that modulates the expression or activity of NIP45.

5

45. A method for identifying a protein that interacts with NIP45 comprising:

a) providing a two hybrid assay including a host cell that contains:

i) a reporter gene operably linked to a transcriptional regulatory sequence;

10

ii) a first chimeric gene that encodes a first fusion protein, said first fusion protein including NIP45;

iii) a library of second chimeric genes that encodes second fusion proteins;

wherein expression of the reporter gene is sensitive to interactions between the first

15

fusion protein, the second fusion protein and the transcriptional regulatory sequence;

b) determining the level of expression of the reporter gene in the host cell;

and

c) identifying a protein that interacts with NIP45.

NF-AT-INTERACTING PROTEIN NIP45 AND METHODS OF USE THEREFOR

Abstract


5

Isolated nucleic acid molecules encoding a novel protein, NIP45, that interacts with members of the Nuclear Factor of Activated T cell (NF-AT) family of proteins, are disclosed. The invention further provides antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals carrying a NIP45 transgene. The invention further provides isolated NIP45 proteins and peptides, NIP45 fusion proteins and anti-NIP45 antibodies. Methods of using the NIP45 compositions of the invention are also disclosed, including methods for detecting NIP45 protein or mRNA in a biological sample, methods of modulating NIP45 activity in a cell, and methods for identifying agents that modulate an interaction between NIP45 and an NF-AT family protein.

FIG. 1



FIG. 2






FIG.3

ACAGTGTGGGAGATGGCGGAACCACTGAGGGGACGTGGTCCGAGGTCC	48
TGTCACACCCTCTACCGCCTTGGTGACTCCCTGCACCAGGCTCCAGG	
<u>M A E P L R G R G P R S</u>	12
CGCGGTGGCCGAGGCGCTCGGAGAGCCCGAGGCGCCCGTGGCCGGTGT	96
GCGCCACCGGCTCCGCGAGCCTCTCGGGCTCCGCGGGCACCGGCACA	
<u>R G G R G A R R A R G A R G R C</u>	28
CCTCGGCCCGGCGAGTCTCCGGCTAGGCTCATTCAGACACCGTGCTT	144
GGAGCGCGGGCCGTCAGAGGCCGATCCGAGTAAGGTCTGTGGCACGAA	
<u>P R A R Q S P A R L I P D T V L</u>	44
GTGGACTTGGTCAGTGACAGCGACGAAGAGGTCTTGGAAGTCGACAGAC	192
CACCTGAACCACTACTGTCGCTGCTTCTCCAGAACCTTCAGCGTCTG	
<u>V D L V S D S D E E V L E V A D</u>	60
CCAGTAGAGGTGCCGGTGC CGCCCTCCCGCGCCGGCTAAACCTGAG	240
GGTCATCTCCACGGCCAGCGGGCGAGGGCGCGGCCGATTTGGACTC	
<u>P V E V P V A R L P A P A K P E</u>	76
CAGGACAGCGACAGTGAACAGTGAAGGGCGGCGGAGGGGCTCGGGGA	288
GTCTGTGCTGTCACTGTCACTTCCCGCGCGGCTCCCGGACGCCCT	
<u>Q D S D S D S E G A A E G P A G</u>	92
GCCCCGCGTACATTGGTGCGACGCGCGGCGGCGGCTGCTGGATCCC	336
CGGGGCGCATGTAACCACGCTGCCGCCGCCGCCGACGACCTAGGG	
<u>A P R T L V R R R R R R L L D P</u>	108
GGAGAGGCGCCGGTGGTCCCAGTGTACTCCGGGAAGGTACAGAGCAGC	384
CCTCTCCGCGGCCACAGGGTCACATGAGGCCCTTCCATGTCTCGTCG	
<u>G E A P V V P V Y S G K V Q S S</u>	124
CTCAACCTCATTCCAGATAATTCATCCCTCTTGAAACTGTGCCCTTCA	432
GAGTTGGAGTAAGGTCTATTAAGTAGGGAGAACTTTGACACGGGAAGT	
<u>L N L I P D N S S L L K L C P S</u>	140
GAGCCTGAAGATGAGGCAGATCTGACAAATTCTGGCAGTTCTCCCTCT	480
CTCGGACTTCTACTCCGTCTAGACTGTTTAAGACCGTCAAGAGGGAGT	
<u>E P E D E A D L T N S G S S P S</u>	156
GAGGATGATGCCCTTGCTTCAGGTTCTCCCTGGAGAAAGAAGCTCAGA	528
CTCCTACTACGGGACGGAAGTCCAAGAGGGACCTCTTCTTCGAGTCT	
<u>E D D A L P S G S P W R K K L R</u>	172

FIGURE 4A

AAGAAGTGTGAGAAAGAAGAAAAGAAAATGGAAGAGTTTCCGACCAG TTCTTCACACTCTTTCTCTTTTCTTTTACCTTCTCAAAGGCCTGGTC K K C E K E E K K M E E F P D Q	576 188
GACATCTCTCCTTTGCCCAACCTTCGTCAAGGAACAAAAGCAGAAAG CTGTAGAGAGGAAACGGGGTTGGAAGCAGTTCCCTGTTTTCTGTTCTTTC D I S P L P Q P S S R N K S R K	624 204
CATACGGAGGCGCTCCAGAAGCTAAGGGAAGTGAACAAGCGTCTCCAA GTATGCCCTCCGCGAGGTCTTCGATTCCCTTCACTTGTTTCGACAGAGTT H T E A L Q K L R E V N K R L Q	672 220
GATCTCCGCTCCTGCCTGAGCCCCAAGCAGCACCAGAGTCCAGCCCTT CTAGAGGCGAGGACGGAAGTTCGGTCTCGTCTCAGGTCCGGGAA D L R S C L S P K Q H Q S P A L	720 236
CAGAGCACAGATGATGAGGTGGTCTAGTGAAGGGCCTGTCTTGCCA GTCTCGTGTCTACTACTCCACCAGGATCACCTTCCCGACAGAACGGT Q S T D D E V V L V E G P V L P	768 252
CAGAGCTCTCGACTCTTTTCACTCAAGATCCGGTGCCGGGCTGACCTA GTCTCGAGAGCTGAGAAATGTGAGTTCTAGGCCACGGCCCGACTGGAT Q S S R L F T L K I R C R A D L	816 268
GTGAGACTGCCTGTGAGGATGTGCGAGCCCCCTTCAAGATGTGGTGGAT CACTCTGACGGACAGTCTTACAGCCTCGGGGAAGTCTTACACCACCTA V R L P V R M S E P L Q N V V D	864 284
CACATGGCCAATCATCTTGGGGTGTCTCCAAACAGGATCTTTTGCTT GTGTACCGGTTAGTAGAACCCACAGAGGTTTGTCTTAAGAAAACGAA H M A N H L G V S P N R I L L L	912 300
TTTGGAGAGAGTGAACTGTCTCCTACTGCCACCCCTAGTACCCTAAAG AAACCTCTCTCACTTGACAGAGGATGACGGTGGGGATCATGGGATTTC F G E S E L S P T A T P S T L K	960 316
CTTGAGTGGCTGACATCATTGATTGTGTGGTGCTAGCAAGCTCTTCA GAACCTCACCAGACTGTAGTAACCTAACACACCACGATCGTTCGAGAAGT L G V A D I I D C V V L A S S S	1008 332
GAGGCCACAGAGACATCCCAGGAGCTCCGGCTCCGGGTGCAGGGGAAG CTCCGGTGTCTCTGTAGGGTCTCGAGGCCGAGGCCACGTCCCTTTC E A T E T S Q E L R L R V Q G K	1056 348

FIGURE 4B

GAGAAACACCAGATGTTGGAGATCTCACTGTCTCCTGATTCTCCTCTT CTCTTTGTGGTCTACAACCTCTAGAGTGACAGAGGACTAAGAGGAGAA E K H Q M L E I S L S P D S P L	1104 364
AAGGTTCTCATGTACACTATGAGGAAGCCATGGGACTCTCTGGACAC TTCCAAGAGTACAGTGTGATACTCCTTCGGTACCCTGAGAGACCTGTG K V L M S H Y E E A M G L S G H	1152 380
AAGCTCTCCTTCTTCTTTGATGGGACAAAGCTTTTCAGGCAAGGAGCTG TTCGAGAGGAAGAAGAACTACCCTGTTTCGAAAGTCCGTTCTCTCGAC K L S F F F D G T K L S G K E L	1200 396
CCAGCTGATCTGGGCCTGGAATCCGGAGATCTCATCGAAGTCTGGGGC GGTCGACTAGACCCGGACCTTAGGCCTCTAGAGTAGCTTCAGACCCCG P A D L G L E S G D L I E V W G	1248 412
TGAAGCTCTCACCTGTTTCGGACGCAAAGCCAAGACATGGAGACAATA ACTTCGAGAGTGGGACAAGCCTGCGTTTCGTTCTGTACCTCTGTAT	1296
GCTCCCAATTTTATTATTGTGATTTTTCGCCCCATAAGGGCTAACAGA CGAGGGTTAAAATAATAACACTAAAAAGCGGGGTATTCCTCGATTGTCT	1344
AACTGAATTAGAACTTGTTTACTTATTTTATTCTGGTGCTGGGGATTG TTGACTTAATCTTGAACAAATGAATAAATAAGACCACGACCCCTAAC	1392
AACCCACAGACTATGCACATGCTAAGGATGTATGAAGTGGAGGCAAAAC TTGGGGTCTGATACGTGTACGATTCTTACATACTTCACCTCCGTTTGTG	1440
CAAGGCATTACCTTTAGCCAGCCTCTAGTAGACTGTAGTGTCAAGCAA GTTCCGTAATGGAAATCGGTCGGAGATCATCTGACATCACAGTTCGTT	1488
GTGGCTACTTGGTAGTTGTGTGGCTCTGTGTATGTTTGTGCTGTATTT CACCAGATGAACCATCAACACACCGAGACACATACAAACACGACATAAA	1536
GGCAGCCCCCTGGGGCAGATAGAAGGGACCTTGGCTTCCTACCATTTTC CCGTCGGGGACCCCGTGTATCTTCCCTGGAACCGAAGGGATGGTAAAG	1584

FIGURE 4C

ACGTTGCTGGTGCCCTTTCCTTCATCAGATGACTTCTGTGAAGCTGC TGCAAGCGACCACGGGAAAGGAGTAGTCTACTGAAGACACTTCGACG	1632
CTATGTTGAGTGTGTTGAACTAAATGAGCTCTGCTTTGGGTGTCCAGG GATACAACTCACACAACTTGATTACTCGAGACGAAACCCACAGGTCC	1680
CCTGGGGTTTGTGCCGCACTTGGAGCCAGCAGTGACTTCACTCTGACT GGACCCCAAACACGGCGTCAACCTCGGTCGTCAGTGAAGTGAGACTGA	1728
TGGGACTGAGAATGCATTTCTGGTGGAGACACTCGGGTGCAGAAATA ACCTGACTCTTACGTAAGGACCACCTCTGTGAGCCCACGCTTTAT	1776
TAACAGAAGGTGACATACATGCTGAAGCTGAGGACTAGGTCGAAAGTT ATTGCTCTCCACTGTATGTACGACTTCGACTCCTGATCCAGCTTTCAA	1824
AACGACGTTGCATTTTCAGCCTTGGGTATCCTCTCTGCCTGCCAGGAC TTGCTGCAACGTAAAAGTCGGAACCCATAGGAGAGACGGACGGTCCTG	1872
TCTAGCCAGTGTCTGGTACACACTTCTTGGCATGGACACCTAGGTGGA AGATCGGTCACAGACCATGTGTGAAGAACCGTACCTGTGGATCCAGCT	1920
CGCGGGCGCGATTTCGGCCGACTCGAG GCGCCCGCGCTAAGCCGGCTGAGCTC	1946

FIGURE4D




FIG.5

0919261.1.111698

FIG. 6




FIG. 7A




FIG. 7B



FIG. 7C



FIG. 7D



FIG. 7E




FIG. 7F

FIG. 8





FIG. 9






FIG.10

Declaration, Petition and Power of Attorney For Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

NF-AT-INTERACTING PROTEIN NIP45 AND METHODS OF USE THEREFOR

the specification of which

(check one)

_____ is attached hereto.

X was filed on November 25, 1996 as

Application Serial No. 08/755,584

and was amended on January 21, 1997
(if applicable)

I do not know and do not believe that the subject matter of this application was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to the date of this application, and that said subject matter has not been patented or made the subject of an issued inventor's certificate in any country foreign to the United States on an application filed by me or my legal representatives or assigns more than twelve months prior to the date of this application; that I acknowledge my duty to disclose information of which I am aware which is material to the examination of this application, that no application for patent or inventor's certificate on the subject matter of this application has been filed by me or my representatives or assigns in any country foreign to the United States, except those identified below, and that I have reviewed and understand the contents of the specification, including the claims as amended by any amendment referred to herein.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

09192611 111653

PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

Check one:

☒ no such applications have been filed.

☐ such applications have been filed as follows

EARLIEST FOREIGN APPLICATION(S), IF ANY FILED WITHIN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

Country	Application Number	Date of Filing (month,day,year)	Priority Claimed Under 35 USC 119
			<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/>
			<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/>
			<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/>
			<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/>
			<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/>

ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

CLAIM FOR BENEFIT OF U.S. PROVISIONAL APPLICATION(S)

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

09192611 111698

CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application. As to subject matter of this application which is common to my earlier United States application, if any, described below, I do not believe that the same was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to said earlier application, or in public use or on sale in the United States more than one year prior to said earlier application, that the said common subject matter has not been patented or made the subject of an inventor's certificate issued before the date of said earlier application in any country foreign to the United States on an application, filed by me or my legal representatives or assigns more than twelve months prior to said application and that no application for patent or inventor's certificate on said subject matter has been filed by me or my representatives or assigns in any country foreign to the United States except those identified herein.

(Application Serial No.)

(Filing Date)

(Status)
(patented,pending,aband.)

(Application Serial No.)

(Filing Date)

(Status)
(patented,pending,aband.)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

John A. Lahive, Jr.	Reg. No. 19,788	Amy E. Mandragouras	Reg. No. 36,207
W. Hugo Liepmann	Reg. No. 20,407	Anthony A. Laurentano	Reg. No. 38,220
James E. Cockfield	Reg. No. 19,162	Jane E. Remillard	Reg. No. 38,872
Thomas V. Smurzynski	Reg. No. 24,798	Mark A. Kurisko	Reg. No. 38,944
Ralph A. Loren	Reg. No. 29,325	Jean M. Silveri	Reg. No. 39,030
Thomas J. Engellenner	Reg. No. 28,711	Jeremiah Lynch	Reg. No. 17,425
Giulio A. DeConti, Jr.	Reg. No. 31,503	Lawrence E. Monks	Reg. No. 34,224
Ann Lamport Hammitte	Reg. No. 34,858	Catherine J. Kara	Reg. No. P41,106
Paul Louis Myers	Reg. No. 35,965	Peter J. Rainville	Reg. No. P41,263
Elizabeth A. Hanley	Reg. No. 33,505	Mark D. Russett	Reg. No. P41,281
Michael I. Falkoff	Reg. No. 30,833	Scott D. Rothenberger	Reg. No. P41,277
John V. Bianco	Reg. No. 36,748		

Send Correspondence to:


Lahive & Cockfield, LLP, 60 State Street, Boston, MA 02109

Direct Telephone Calls to: (name and telephone number)

Catherine J. Kara, (617) 227-7400

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor	
Laurie H. Glimcher	
Inventor's signature	Date
	4/30/97
Residence	
51 Hampshire Street, West Newton, Massachusetts 02165	
Citizenship	
U.S.A.	
Post Office Address (if different)	

Full name of second inventor, if any Martin R. Hodge	
Inventor's signature	Date
Residence 39 Crawford Street, Arlington, Massachusetts 02174	
Citizenship U.S.A.	
Post Office Address (if different)	

09192611.111698

Declaration, Petition and Power of Attorney For Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

NF-AT-INTERACTING PROTEIN NIP45 AND METHODS OF USE THEREFOR

the specification of which

(check one)

_____ is attached hereto.

X was filed on November 25, 1996 as

Application Serial No. 08/755,584

and was amended on January 21, 1997
(if applicable)

I do not know and do not believe that the subject matter of this application was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to the date of this application, and that said subject matter has not been patented or made the subject of an issued inventor's certificate in any country foreign to the United States on an application filed by me or my legal representatives or assigns more than twelve months prior to the date of this application; that I acknowledge my duty to disclose information of which I am aware which is material to the examination of this application, that no application for patent or inventor's certificate on the subject matter of this application has been filed by me or my representatives or assigns in any country foreign to the United States, except those identified below, and that I have reviewed and understand the contents of the specification, including the claims as amended by any amendment referred to herein.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

09132611 111653

PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

Check one:

☒ no such applications have been filed.

☐ such applications have been filed as follows

EARLIEST FOREIGN APPLICATION(S), IF ANY FILED WITHIN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

Country	Application Number	Date of Filing (month,day,year)	Priority Claimed Under 35 USC 119
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

CLAIM FOR BENEFIT OF U.S. PROVISIONAL APPLICATION(S)

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

09192611.111698

CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application. As to subject matter of this application which is common to my earlier United States application, if any, described below, I do not believe that the same was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to said earlier application, or in public use or on sale in the United States more than one year prior to said earlier application, that the said common subject matter has not been patented or made the subject of an inventor's certificate issued before the date of said earlier application in any country foreign to the United States on an application, filed by me or my legal representatives or assigns more than twelve months prior to said application and that no application for patent or inventor's certificate on said subject matter has been filed by me or my representatives or assigns in any country foreign to the United States except those identified herein.

(Application Serial No.)

(Filing Date)

(Status)
(patented,pending,aband.)

(Application Serial No.)

(Filing Date)

(Status)
(patented,pending,aband.)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

John A. Lahive, Jr.	Reg. No. 19,788	Amy E. Mandragouras	Reg. No. 36,207
W. Hugo Liepmann	Reg. No. 20,407	Anthony A. Laurentano	Reg. No. 38,220
James E. Cockfield	Reg. No. 19,162	Jane E. Remillard	Reg. No. 38,872
Thomas V. Smurzynski	Reg. No. 24,798	Mark A. Kurisko	Reg. No. 38,944
Ralph A. Loren	Reg. No. 29,325	Jean M. Silveri	Reg. No. 39,030
Thomas J. Engellenner	Reg. No. 28,711	Jeremiah Lynch	Reg. No. 17,425
Giulio A. DeConti, Jr.	Reg. No. 31,503	Lawrence E. Monks	Reg. No. 34,224
Ann Lamport Hammitte	Reg. No. 34,858	Catherine J. Kara	Reg. No. P41,106
Paul Louis Myers	Reg. No. 35,965	Peter J. Rainville	Reg. No. P41,263
Elizabeth A. Hanley	Reg. No. 33,505	Mark D. Russett	Reg. No. P41,281
Michael I. Falkoff	Reg. No. 30,833	Scott D. Rothenberger	Reg. No. P41,277
John V. Bianco	Reg. No. 36,748		

Send Correspondence to:

Lahive & Cockfield, LLP, 60 State Street, Boston, MA 02109

Direct Telephone Calls to: (name and telephone number)

Catherine J. Kara, (617) 227-7400

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor	
Laurie H. Glimcher	
Inventor's signature	Date
Residence	
51 Hampshire Street, West Newton, Massachusetts 02165	
Citizenship	
U.S.A.	
Post Office Address (if different)	

Full name of second inventor, if any Martin R. Hodge	
Inventor's signature <i>Martin R. Hodge</i>	Date Mar 1977
Residence 39 Crawford Street, Arlington, Massachusetts 02174	
Citizenship U.S.A.	
Post Office Address (if different)	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Randell L. Mills

Serial No.: N/A

Filed: Herewith

For: NFAT-Interacting Protein NIP45 and Methods
of Use Therefor

Attorney Docket No.: HUI-026DV

Group Art Unit:

Examiner:

Assistant Commissioner for Patents
Washington, D.C. 20231

ASSOCIATE POWER OF ATTORNEY

Sir:

The undersigned attorney has the power of attorney in the subject application.

She hereby grants an associate power to:

Megan E. Williams, Ph.D.
Registration No. 43,270
Lahive & Cockfield, LLP
28 State Street
Boston, MA 02109

Please continue to forward all written and telephonic communications to Amy E.
Mandragouras at the address and telephone number listed below.

Respectfully submitted,

Amy E. Mandragouras
Registration No. 16,207
Attorney for Applicants

LAHIVE & COCKFIELD, LLP
28 State Street
Boston, MA 02109
Tel. (617) 227-7400
Dated: November 16, 1998